Page: 1
Protocol Number: MB102138
IND Number: 68,652
EUDRACT Number 2015-005041-31
Date: 15-Jan- 2016
Revised Date: 20-Sep-2017
Clinical Protocol MB102138
(AZ study number: D1690C00017)
A 24 Week, Multicenter, Randomized, Double -Blind, Parallel Group, Phase 3 Trial with a 
28Week L ong Term Safety  Extension Period Evaluating the Safety  and Efficacy  of 
Dapagliflozin 10 mg in T2DM Patients aged 10
-24 years.
Revised Protocol Number: 03
Incorporates amendments :01 & 02& 03
Medical Monitor
 
Sponsor: AstraZeneca AB, 151 85 Södertälje, Sweden

Clinical Protocol MB102138
BMS -512148 dapagliflozin
Revised Protocol No: 03
Date: 20-Sep- 2017 2This document is the confidential and proprietary information of Bristol -Myers Squibb 
Company and its global affiliates (BMS). By reviewing this document, you agree to keep it 
confidential and to use and disclose it solely for the purpose of assessing whether your 
organization will participate in and/or the performance of the proposed BMS -sponsored 
study. Any permitted disclosures will be made only on a confidential "need to know" basis 
within your organization or to your independent ethics committee(s). Any other use, copying, 
disclosure or dissemination of this information is strictly prohibited unless expressly 
authorized in writing by BMS. Any supplemental information (eg, amendments) that may 
be added to this document is also confidential and proprietary to BMS and must be kept in 
confidence in the same manner as the contents of this document. Any person who receives 
this document without due authorization from BMS is request ed to return it to BMS or 
promptly destroy it. All other rights reserved. References to BMS in this protocol may apply 
to partners to which BMS has transferred obligations, eg, a Contract Research Organization 
(CRO).
This submission document contains confi dential commercial information, disclosure of which is 
prohibited without providing advance notice to AstraZeneca and opportunity  to object.
This Clinical Study  Protocol has been subject to a peer review according to AstraZeneca Standard 
procedures. The clinical study  protocol is publicly registered and the results are disclosed and/or 
published according to the AstraZeneca Global Policy  on Bioethics and in compliance with all 
prevailing laws and regulations.
Replace all previous version(s) of the protocol with this revised protocol and please provide a copy 
of this revised protocol to all study  personnel under your supervision, and archive the previous 
versions.

Clinical Protocol MB102138
BMS -512148 dapagliflozin
Revised Protocol No: 03
Date: 20-Sep- 2017 3DOCUMENT HISTORY
Document Date of Issue Summary of Change
Revised 
Protocol 0320-Sep- 2017 Incorporates Amendment 03
Amendment 03 20-Sep- 2017The purpose of this protocol amendment is to increase the number of 
subjects randomized in the study to ensure that at least 50 subjects will 
complete the 24 -week treatment period on investigational product and 
the Week 24 assessment .
Revised 
Protocol 0213-Feb- 2017 Incorporates Amendment 0 2
Amendment 02 13-Feb- 2017The purpose of this protocol amendm ent is to 
reflect the end of 
Bristol -Myers Squibb’s role in the study, and to update the details of the 
Medical Monitor. The duration of the screening period has been 
extended, and details relating to the masking of spot urine glucose, the 
study weeks relating to lack of glycemic control criteria for initiation of 
rescue medication , and theuse of third party vendors for Lost to 
Follow -Up subjects have been clarified. 
The 24 -hour emergency telephone numbers and SAE reporting details 
have been updated to PRA numbers .
Revised 
Protocol 0115-Jan-2016 Incorporates Amendment 01
Amendment 01 15-Jan-2016The purpose of this amendment is to incorporate new  safety information 
related to diabetic ketoacidosis (DKA) as reflected in Dapagliflozin IB 
version 12, and correct typographical errors and discrepancies within the 
protocol .
Original 
Protoc ol09-Nov-2015 Not applicable
Clinical Protocol MB102138
BMS -512148 dapagliflozin
Revised Protocol No: 03
Date: 20-Sep- 2017 4TABLE OF CONTENTS
DOCUMENT HISTORY ........................................................................................................................... 3
SYNOPSIS ........................................................................................................................................ 7
1INVESTIGATIONAL PL AN............................................................................................................... 13
1.1 Study Rationale ......................................................................................................................... 14
1.2 Research Hypothesis ................................................................................................................. 15
1.3 Objectives(s) .............................................................................................................................. 15
1.3.1 Primary Objectives .............................................................................................................. 15
1.3.2 Secondary Objectives ........................................................................................................... 15
1.3.3 Safety Objectives .................................................................................................................. 15
1.3.4 Exploratory Objectives ........................................................................................................ 16
1.4 Product Development Background ............................................................................................ 16
1.5 Overall Risk/Benefit Assessment .............................................................................................. 17
2ETHICAL CONSIDERATIO NS.......................................................................................................... 17
2.1 Good Clinical Practice ............................................................................................................... 17
2.2 Institutional Review Board/Independent Ethics Committee ..................................................... 17
2.3 Informed Consent ...................................................................................................................... 18
3INVEST IGATIONAL PLAN ............................................................................................................... 19
3.1 Study Design and Duration ....................................................................................................... 19
3.2 Post Study Access to Therapy ................................................................................................... 20
3.3 Study Population ....................................................................................................................... 20
3.3.1 Inclusion Criteria ................................................................................................................. 20
3.3.2 Exclusion Criteria ................................................................................................................ 23
3.3.3 Women of Childbearing Potential ....................................................................................... 25
3.4 Concomitant Treatments ........................................................................................................... 25
3.4.1 Prohibited and/or Restricted Treatments ............................................................................. 25
3.4.2 Other Restrictions and Precautions ..................................................................................... 25
3.5 Discontinuation of Subjects following any Treatment with Study Drug ................................... 26
3.5.1 Procedures for handling patients incorrectly enrolled or randomized ............................... 27
3.5.2 Rescue Guidelines for Subjects with Protocol -Defined Lack of Glycemic Control ............. 27
3.5.3 Discontinuation Guidelines due to Protocol -Defined Hypoglycemia Episodes .................. 28
3.5.4 Discontinuation Guidelines due to Diabetic Ketoacidosis (DKA) ....................................... 29
3.6 Post Study Drug Study Follow -up............................................................................................. 30
3.6.1 Withdrawal of Consent ........................................................................................................ 30
3.6.2 Lost to Follow -Up................................................................................................................ 30
3.6.3 Survey of Subject Vital Status .............................................................................................. 31
4STUDY DRUG ...................................................................................................................................... 32
4.1 Investigational Product .............................................................................................................. 33
4.2 Non-investigational Product ...................................................................................................... 33
4.3 Storage and Dispensing ............................................................................................................. 33
4.4 Method of Assigning Subject Identification .............................................................................. 34
4.5 Selection and Timing of Dose for Each Subject ........................................................................ 34
4.6 Blinding/Unblinding .................................................................................................................. 35
4.7 Treatment Compliance .............................................................................................................. 35
4.8 Destruction of Study Drug......................................................................................................... 36
4.9 Return of Study Drug ................................................................................................................ 36
4.10 Retained Samples for Bioavailability / Bioe quivalence ............................................................ 36
5STUDY ASSESSMENTS AN D PROCEDURES ................................................................................ 37
5.1 Flow Chart/Time and Events Schedule ..................................................................................... 37
5.1.1 Retesting During Screening or Lead -in Period ................................................................... 46
Clinical Protocol MB102138
BMS -512148 dapagliflozin
Revised Protocol No: 03
Date: 20-Sep- 2017 55.2 Study Materials .......................................................................................................................... 46
5.3 Safety Assessments ................................................................................................................... 47
5.3.1 Self-Monitored Blood Glucose (SMBG), Self -Monitored blood Ketones and Guidance on 
Management and Reporting of Hypoglycemia Episodes ..................................................... 47
5.3.2 Guidance on Assessment of Urinary Tract Infections & Hematuria ................................... 49
5.3.3 Guidance on Assessment of Hepatic Laboratory Abnormalities ......................................... 50
5.3.4 Physical Examination .......................................................................................................... 51
5.3.5 Blood Pressure and Heart Rate ........................................................................................... 51
5.3.6 Guidance on Volume Depletion ........................................................................................... 52
5.3.7 Supplemental Visits .............................................................................................................. 52
5.3.8 Imaging Assessment for the Study ....................................................................................... 52
5.4 Efficacy Assessments ................................................................................................................ 52
5.5 Pharmacokinetic Assessments ................................................................................................... 52
5.6 Biomarker Assessments ............................................................................................................. 53
5.7 Outcomes Research Assessments .............................................................................................. 53
5.8 Other Assessments ..................................................................................................................... 53
5.8.1 Diet and Exercise Counseling .............................................................................................. 53
5.8.2 Weight and Height ............................................................................................................... 54
5.9 Results of Central Assessments ................................................................................................. 54
6ADVERSE EVENTS ............................................................................................................................. 54
6.1 Serious Adverse Events ............................................................................................................. 55
6.1.1 Serious Adverse Event Collection and Reporting ................................................................ 56
6.2 Nonserious Adverse Events ....................................................................................................... 57
6.2.1 Nonserious Adverse Event Collection and Reporting .......................................................... 58
6.3 Laboratory Test Result Abnormalities ...................................................................................... 58
6.4 Pregnancy .................................................................................................................................. 58
6.5 Overdose .................................................................................................................................... 59
6.6 Potential Drug Induced Liver Injury (DILI) .............................................................................. 59
6.7 Other Safety Considerations ...................................................................................................... 59
7DATA MONITORING COMM ITTEE AND OTHER COMM ITTEES ......................................... 59
7.1 Data Monitoring Committees .................................................................................................... 59
7.2 Hepatic Adjudication Committee .............................................................................................. 59
7.3 Diabetic Ketoacidosis (DKA) Adjudication Committee ........................................................... 60
8STATISTICAL CONSIDER ATIONS ................................................................................................. 60
8.1 Sample Size Determination ....................................................................................................... 60
8.2 Populations for Analyses ........................................................................................................... 60
8.3 Endpoints ................................................................................................................................... 61
8.3.1 Primary Endpoint(s) ............................................................................................................ 61
8.3.2 Secondary Endpoint(s) ......................................................................................................... 61
8.3.3 Exploratory Endpoint(s) ...................................................................................................... 61
8.4 Analyses .................................................................................................................................... 61
8.4.1 Demographics and Baseline Characteristics ....................................................................... 61
8.4.2 Efficacy Analyses ................................................................................................................. 61
8.4.3 Safety Analyses .................................................................................................................... 62
8.4.4 Pharmacokinetic Analyses ................................................................................................... 63
8.4.5 Biomarker Analyses ............................................................................................................. 63
8.4.6 Outcomes Research Analyses .............................................................................................. 63
8.4.7 Other Analyses ..................................................................................................................... 63
8.5 Interim Analyses ........................................................................................................................ 63
9STUDY MANAGEMENT ..................................................................................................................... 63
9.1 Compli ance................................................................................................................................ 63
Clinical Protocol MB102138
BMS -512148 dapagliflozin
Revised Protocol No: 03
Date: 20-Sep- 2017 69.1.1 Compliance with the Protocol and Protocol Revisions ....................................................... 63
9.1.2 Monitoring ........................................................................................................................... 64
9.1.3 Invest igational Site Training ............................................................................................... 65
9.2 Records ...................................................................................................................................... 65
9.2.1 Records Retention ................................................................................................................ 65
9.2.2 Study Drug Records ............................................................................................................. 65
9.2.3 Case Report Forms .............................................................................................................. 66
9.3 Clinical Study Report and Publications ..................................................................................... 66
10 GLOSSARY OF TERMS ................................................................................................................. 68
11 LIST OF ABBREVIATIONS ........................................................................................................... 69
12 REFERENCES .................................................................................................................................. 72
APPENDIX 1 CENTRAL LABORATORY A SSESSMENTS ....................................................... 74
APPENDIX 2 SUSTAINED ELEVATED L IVER SAFETY ABNORMAL ITIES FLOW 
CHART ....................................................................................................................... 78
APPENDIX 3 TANNER ASSESSMENT SC ALE ........................................................................... 79
APPENDIX 4 APPENDIX REFERENCES ..................................................................................... 81
Clinical Protocol MB102138
BMS -512148 dapagliflozin
Revised Protocol No: 03
Date: 20-Sep- 2017 7SYNOPSIS
Clinical Protocol MB102138 (AZ study number: D1690C00017)
Protocol Title: A 24 Week  Multicenter, Random ized, Double -Blind, Parallel Group, Phase 3 Trial with a 28 Week  
Long Term  Safety Extension Period Evaluating the Safety and Efficacy of Dapagliflozin 10 mg in T2DM Patients 
aged 10 -24 years.
Investigational Product(s), Dose and Mode of Adm inistration, Duration of Treatment with Investigational 
Product(s): Dapagliflozin 10mg or placebo tablets administered orally once daily for the 24-week double -blind ed 
short -term treatment period 
anddapagliflozin 10mg tablets administered orally once daily for the 28-week open -label 
safety extension.
Study Phase: 3b
Research Hypothesis: Dapagliflozin results in a greater mean reduction from baseline in glycated hemoglobin 
(HbA1c) compared to placebo after 24 weeks of double
-blind add-on treatment in patients aged 10 to less than 25years 
with T2DM who have inadequate glycemic control on d iet and exercise with metformin or insulin metformin.
Objectives:
Prim ary Objective:
To compare the mean change from baseline in HbA1c achieved with dapagliflozin against the mean achieved with 
placebo after 24 weeks of double- blind add-on treatment in patients aged 10 to less than 25years with T2DM who 
have inadequate glycemic control on diet and exercise with metformin or insulin  metformin .
Secondary Objectives :
To compare the mean change from baseline in Fasting Plasma Glucose (FPG) achieved with dapagliflozin against 
the mean achieved with placebo after 24 w eeks of double -blind add -on treatment in patients aged 10 to less than 
25 years with T2DM who have inade quate glycemic control on diet and exercise with metformin or insulin 
metformin .
To compare the percentage of subjects who require glycemic rescue or discontinuation due to lack of glycemic 
control with dapagliflozin against the percentage with placebo over the 24 weeks of double- blind add-on treatment 
in patients aged 10 to less than 25 years with T2DM w ho have inadequate glycemic control on diet and exercise 
with metformin, or insulin metformin .
To compare the percentage of subjects with baseline HbA1 c > 7% who achieve a HbA1c level <7% with 
dapagliflozin against the percentage achieved with placebo after 24weeks of double -blind add-on treatment in 
patients aged 10 to less than 25 years with T2DM who have inadequate glycemic control on diet and exerc ise 
with metformin, or insulin metformin .
Safety Objectives:
To assess the safety and tolerability of dapagliflozin as add -on treatment in patients aged 10 to less than 25 years 
with T2DM who have inadequate glycemic control on diet and exercise with metformin or insulin metformin 
when administered for up to 24 w eeks of short -term therapy and 52 w eeks of total therapy.
To assess the percentage of subjects who experience hypoglycemia with dapagliflozin against the percentage 
achieved with placebo as add-on treatment in patients aged 10toless than 25 years with T2DM who have 
inadequate glycemic control on diet and exercise with metformin, or insulin metformin when adm inistered for 
up to 24 weeks.
To assess markers of grow th and maturation, the inciden ce of diabetic ketoacidosis (DKA) , and changes in 
markers of bone health with dapagliflozin against those observed with placebo as add-on treatment in patients 
aged 10 to less than 25 years with T2DM who have inadequate glycemic control on diet and exercis e with 
metformin ,or insulin metformin when administered for up to 24 w eeks.
Clinical Protocol MB102138
BMS -512148 dapagliflozin
Revised Protocol No: 03
Date: 20-Sep- 2017 8Exploratory Objectives:
To explore the pharmacokinetics ( PK)and exposure -response relationship of dapagliflozin in patients aged 10 to 
less than 25 years with T2DM based on the collection of population PK samples .
To explore the mean change from baseline in HbA1c achieved with dapagliflozin after 52weeks of add-on 
treatment in patients aged 10 to less than 25 years with T2DM who have inadequate glycemic control on diet and 
exercise with metformin or insulin metformin .
To explore the mean change from baseline in FPG achieved with dapagliflozin after 52weeks of add-on treatment 
in patients aged 10 to less than 25 years with T2DM who have inadequate glycemic control on diet a nd exercise 
with metformin or insulin 
metformin .
To explore the percentage of subjects who require glycemic rescue or discontinuation due to lack of glycemic 
control with dapagliflozin over the 52 weeks of add-on treatment in patients aged 10 to less than 25years with 
T2DM who have inadequate glycemic control on diet and exercise w ith metformin or insulin  metformin .
To explore the percentage of subjects with baseline HbA1c >7% who achieve a HbA1c level <7% with 
dapagliflozin after 52 w eeks of add -on treatment in patients aged 10 to less than 25 years with T2DM who have 
inadequate glycemic control on diet and exercise with metformin or insulin metformin .
Study Design: The study will be a prospective, multi -center, 24 -week, placebo controlled, double -blind randomized 
study with a 28-week open -label safety extension. Subjects 10 years and < 25 years of age, with confirmed diagnosis 
of T2DM ,who are being treated with diet and exercise and a stable dose of metformin immediate release (IR)or 
extended release (XR)(at least 1000 mg daily) 
for a minimum of 8 weeks prior to screening, or a stable dose of insulin 
for a minimum of 8weeks prior to screening, or a stable combination of metformin and insulin for a minimum of 
8weeks prior to screening, will b e screened against the inclusion and exclusion criteria. Eligible subjects meeting all 
criteria will enter a 4-week placebo lead-in period. Subjects will be instructed to follow  a diet and exercise program 
(in accordance with the American Diabetes Associat ion [ ADA ]or sim ilar national guidelines) for the duration of the 
study. Subjects will maintain their baseline types of antidiabetic therapy throughout the study. 
Recruitment (randomization) of subjects 18 and < 25 years old will be limited to <40% of subjects. Recruitment 
(randomization) of subjects 10 and  15 years old w ill include at least 20% of subjects. 
After the lead-in period, at least 66 subjects with HbA1c 6.5% and 11% at screening will be randomized 1:1 to 
receive oral blinded dapagliflozin 10 mg or placebo, stratified by gender, age (< 18 vs. 18 years and 15 years vs. 
>15 to < 18 years) and baseline medication (metformin alone, insulin metformin). After completion of the 24 -week 
short -term treatment period, all subjects will enter the 28-week open -label safety extension period for safety 
monitoring. All subjects will receive dapagliflozin 10mg for the duration of this period. This will be follow ed by a 
4-week post-treatment safety follow -up period.
Subjects who disconti nue study drug before the end of the study treatment period will enter a non-treatment, follow -up 
phase, in which subjects w ill follow  their visit schedules with modified assessments until study completion.
Safety measures will be collected throughout the study. This will include regular self-monitored blood glucose 
(SMBG) levels, self -monitored blood ketone levels, and monitoring of grow th and development. 
Population PK samples will be collected pre-dose and approximately 2 hours post-dose (1hour) during the 
Week16and 24 visits.
Clinical Protocol MB102138
BMS -512148 dapagliflozin
Revised Protocol No: 03
Date: 20-Sep-2017 9Study Schematic:
During the course of the trial, subjects may be eligible for the addition of open -label rescue medication to their blinded 
treatment regimen in order to treat ongoing hyperglycemia. Insulin will be initiated or up -titrated as rescue.
Pre-specified glycemic criteria (see Table 1 below ), based upon SMBG FPG, or single central laboratory FPG and 
repeat confirmatory FPG have been established during the treatment period, starting at Day 1 , and up to the Week 52 
visits to determine eligibili ty for open -label rescue medication. For subjects on baseline insulin, persistently increased 
doses of insulin 20% or more above baseline dose, despite advice and counsel to keep the insulin dose stable, may be 
considered another potential manifestation ofpoor glycemic control, and should be evaluated for rescue. Any 
permanent changes in dose of basal insulin should be done after evaluation of rescue criteria, including both SMBG 
and central laboratory FPG values. 
Table 1: Lack of Glycemic Control Criteri a for Initiation of Rescue Medication
Study week Rescue criterion
From  Day 1 visit up to and 
including Week 24 visitFPG > 13.3 mmol/L (240 mg/d L) based on SMBG for 3 consecutive days 
followed by a confirmatory central laboratory FPG or
Single central laboratory FPG followed by a confirmatory central laboratory 
FPG
Follow ing Week 24 visit up to 
and not including Week 52 
visitFPG > 10 mmol/L (180 mg/d L) based on SMBG for 3 consecutive days 
followed by a confirmatory central laboratory FPG or
Single central laboratory FPG followed by a central laboratory FPG or
HbA1c >8.0%
Study Population: For entry into the study, the following criteria MUST be met. The full inclusion/exclusion criteria 
are found in Section 3.3 of the protocol.
Key Inclusion Crit eria:
Provision of informed consent prior to any study -specific procedures
Males and females , ages 10 years of age, up to but not including 25 years of age at the time of randomization
Previously diagnosed as having T2DM for at least 2 months by World Heal th Organization (WHO )/ADA 
diagnostic criteria
HbA1c 6.5% and 11% obtained at screening visit

Clinical Protocol MB102138
BMS -512148 dapagliflozin
Revised Protocol No: 03
Date: 20-Sep- 2017 10Currently on diet and exercise and a stable dose of metformin (at least 1000 mg daily) for a minimum of 8 weeks, 
or stable dose of insulin for a minimum of 8 weeks, or a stable combination of metformin (at least 1000 mg daily) 
and insulin for a minimum of 8 w eeks prior to screening
FPG 255 mg/dL ( 14.2 mmol/L) obtained at screening visit
Key Exclusion Criteria:
Previous diagnosis of Type 1 diabetes
Diabetes ketoacidosis (DKA) within 6 months of screening
Current use of the following medications for the treatment of diabetes, or use within the specified timeframe prior 
to screening for the main study:
-Eight weeks: sulfonylureas, alpha glucosidase inhibitors, metiglinide, oral or injectable incretins or incretin 
mimetics or other antidiabetes medications not otherwise specified
-Sixteen weeks: thiazolidinediones
-Any previous history or current use of asodium glucose cotransporter -2 (SGLT -2)inhibitor, including
dapagliflozin
Initiation or discontinuation of prescription or non-prescription weight loss drugs within 8 weeks of screening. 
Use of prescription or non -prescription weight loss drugs must be stable during the study .
Pregnant, positive serum pregnancy te st, planning to become pregnant during the clinical trials, or breastfeeding
History of unstable or rapidly progressive renal disease
History of unresolved vesico -ureteral reflux
Replacement or chronic systemic corticosteroid therapy, defined as any dose o f systemic corticosteroid taken for 
>4 weeks within 3 months prior to the Day 1 visit
Note: Topical, nasal, or inhaled corticosteroids are allow ed
Abnorm al renal function, which is defined in subjects < 18 years of age as an estimated glomerular filtratio n rate 
(eGFR) calculated by the Schwartz Formula < 80 mL/min/1.73 m2(1.33 mL/s) ,and in subjects 18 years as an 
eGFR calculated by the Modified Diet in Renal Disease ( MDRD )Formula <60 mL/min/1.73 m2(1.33 mL/s)
Presence of either: antibodies to glutam ic acid decarboxylase (GAD) or protein tyrosine phosphatase -like protein 
antibodies (IA- 2)
An abnormal thyroid stimulating horm one (TSH )value at screening will be further evaluated for free T4. Subjects 
with abnormal free T4 values will be excluded .
Hem aturia (confirmed by microscopy at screening) with no explanation as judged by the Investigator up to 
randomization
Anemia of any etiology defined as hemoglobin 10.7 g/dL (107 g/L) for females and 11.3 g/dL (113 g/L) for 
males. Subjects who are considere d to have anemia according to local guidelines should be excluded .
Volume -depleted subjects. Subjects at risk for volume depletion due to co-existing conditions or concomitant 
medications, such as loop diuretics, should carefully monitor their volume statu s.
Study Drug: includes both Investigational [Medicinal] Products (IP/IMP) and Non -investigational [Medicinal] 
Products (Non -IP/Non -IMP) as listed:
Study Drug for BMS-512148
Medication Potency IP/Non -IP
Dapagliflozin 10 mg IP
Placebo Matching 
Dapagliflozin0 mg IP
Clinical Protocol MB102138
BMS -512148 dapagliflozin
Revised Protocol No: 03
Date: 20-Sep- 2017 11Study Assessments:
Dose and Treatment Regimens 
Dapagliflozin 10 mg tablets or matching placebo tablets, administered orally once daily, will be provided for the 
24-week blinded treatment period. Dapagliflozin 10mg tablets administered orally once daily, will be provided for 
the 28 -week site and subject blinded long-term extension.
During the study, diet and exercise w ill be reinforced at each visit.
Safety Assessments
Self-monitored blood glucose (SMBG) and reporting of hypoglycem ia
Glucose meters will be supplied to each study site. Subjects should be asked to self-monitor their blood glucose at 
least once per day and when symptoms suggestive of hypoglycemia occur. The Investigator may require more frequent 
readings based on local clinical practice. The glucose values should be review ed by the site to identify any unusual 
high or low  values .
Self-monitored blood ketones and reporting of DKA
Subjects and their family members must be aware o f the possibility that DKA may occur, the signs and symptoms and 
the dangers associated w ith DKA. Subjects will receive a combined glucose and ketone meter and sufficient supplies 
for testing at the entry into Lead -In (Week -4 visit). Subjects will also be trained in the procedure of conducting blood 
ketone testing according to the manufacture r’s specifications. The blood ketone values should be recorded and will be 
reviewed by the site to i dentify any unusual high values.
Assessment of growth and maturatio n
Grow th and maturation will be assessed through the collection of relevant physical measurements and specific 
laboratory tests,
Laboratory Safety Assessments
Blood and urine samples for determination of clinical chemistry, hematology , and urinalysis will be taken at the times 
indicated in the protocol.
The Investigator should make an assessment of the available results with regard to clinically relevant abnormalities.
Statistical Considerations:
Sample Size:
Given the anticipated challenges to recruitment with this population, a partial extrapolation approach was used to 
better inform the sample size determination.
A probability estimate was determ ined using clinical trial simulation from a non-linear mixed effects model for the 
relationship betw een dapagli flozin PK and HbA1c response in adult T2DM subjects. Adjustments were made to the 
model for expected differences in the covariate effects on PK and pharmacodynamic (PD) parameters due to the 
differences in baseline characteristics between adult and pediatr icT2DM subjects. The simulation allowed for the 
sample size to be reduced while maintaining 85% probability of demonstrating superiority to placebo for dapagliflozin 
10 mg. In order to inform the design of this study, a Bayesian approach was employed to predict the potential efficac y 
of dapagliflozin on HbA1c in pediatric patients from the existing data and knowledge in adult T2DM patients.
Simulation results suggest a difference versus placebo in HbA1c of -0.78% for dapagliflozin 10mg. Based on this 
est
imated treatment difference of 0.78% and assuming a standard deviation of 0.9% for change from baseline in 
HbA1c at Week 24, a sample size of 25 per treatment group has 85% power to demonstrate the superiority of 
dapagliflozin 10 mg to placebo (where super iority is defined as a placebo -corrected HbA1c at 24weeks indicating 
greater improvement that is statistically significant) at a two-sided alpha level of 5 percent. To ensure that at least 
50subjects will complete the 24-week treatment period on investig ational product and the Week 24 assessment, at 
least 66 subjects will be randomized .
Clinical Protocol MB102138
BMS -512148 dapagliflozin
Revised Protocol No: 03
Date: 20-Sep- 2017 12Endpoints:
Prim ary endpoint
1.Change from baseline in HbA1c at Week 24
Secondary endpoints
2.The change from baseline in FPG at W eek 24
3.The percentage of subjects who require glycemic rescue medication or discontinuation due to lack of glycemic 
control over 24 w eeks double -blind treatment
4.The percentage of subjects with baseline HbA1c > 7% who achieve HbA1c level < 7% at Week 24
Safety endpoints
The assessment of safety will bebased on the analyses of adverse events (AEs) , vital signs, physical exam inations, 
electrocardiograms (ECGs) , hypoglycemia, elevated plasma ketone level, and clinical laboratory evaluations. All 
safety analyses will be performed using the Treated Subjects Data Set.
Analyses:
Statistical Approach and Assumptions
The primary analysis of the primary endpoint, change in HbA1c from baseline to Week 24, w ill be based on a mixed 
model with repeated measures (MMRM) including all scheduled time points following randomization up to and 
including Week 24. The primary analysis will only include measurements prior to the administration of rescue 
medication. Measurements made follow ing rescue administration will be included in sensitivity analysis. Various 
sensitivity an alyses will be specified in the Statistical Analysis Plan to assess the robustness of the primary analyses, 
including sensitivity analyses of all data pre -and post -rescue.
Point estimates and 95% confidence intervals for the mean change in HbA1c for each t reatment group as well as the 
difference in the estimated mean change between the dapagliflozin treatment group and placebo will be calculated. 
The p -value of the difference in Week 24 estimates between dapagliflozin and placebo w ill be presented.
Safety A nalyses
Safety analyses will include treatm ent group summaries of the incidence of AEsand marked laboratory abnormalities, 
the percentages of subjects experiencing hypoglycemia as well as the number and severity of hypoglycemic events, 
the incidence of el evated plasma ketone level ,vital signs, and laboratory test parameters. 
Summaries will include the number of patients with events by specified system organ classes and preferred terms.
Clinical Protocol MB102138
BMS -512148 dapagliflozin
Revised Protocol No: 03
Date: 20-Sep- 2017 131 INVESTIGA TIONA L PLA N
Type 2 diabetes mellitus (T2DM) is a complex and multifactorial metabolic disorder with 
contributions from genetic, behavioral, and environmental risk factors. Despite a wealth of 
information concerning T2DM in adults, data unique to the pediatric age group regarding the 
pathophy siology  and therapy  for T2DM are limited.1
As in adults, T2DM in children is characterized by  hypergl ycemia associated with initial relative 
insufficiency  of insulin secretion and increased insulin resistance, and is ultimately  often followed 
by pancreatic β-cell failure .2,3,4A potentially  important difference between adults and pediatric 
patients with T2DM is that in the natural course of T2DM in pediatric patients, the glucose 
dysregulation may develop over a much more rapid time frame than is seen in adults.5This may 
be a contributing factor to the tendency for poorer prognosis for microvascular and macrovascular 
diabetic complications forpediatric patients with T2DM as they become adults.6An additional 
factor unique to the development of T2DM in the pediatric age range is the potential additive 
contribution and impact of the insulin resistance of puberty , which, although a natural phenomenon 
during pubertal development, may have a negative influence on and potentially  exacerbate 
glycemic d ysregulation in susceptible children.5
As with adults, it is expected that children and adolescents with T2DM are at risk for eventuall y 
developing diabetes -related micro- and macrovascular complications with higher glycemic levels.1
Data from a number of small studies conducted in limited ethnic groups have confirmed an 
increased risk of microvascular complications1,7in pediatric patients with T2DM compared with 
children and adolescents without diabetes. For example, microalbuminuria, macroalbuminuria, 
and hypercholesterolemia have all shown an increased tendency  to develop in Pima Indian children 
with T2DM . Among Japanese pediatric patients, retinopathy has been observed at a similar rate in 
those with type 1 and T2DM , although it appears to be less common in pediatric patients compared 
with adults with T2DM . A study  in Australia found that pediatric patients with T2DM have 
significantl y higher rates of microalbuminuria and hypertension than those with type 1 diabetes, 
despite shorter duration of disease and lower glycosylated hemoglobin (HbA1c).8Additional small 
studies have shown an increased occurrence of renal disease (Japanese), non -alcoholic fatty liver 
disease (the Manitoba Cree), and cardiovascular mortalit y associated with hypertension and 
dyslipidemia in pediatric patients with T2DM .9
There is evidence in adults from the UK Prospective Diabetes Stud y (UKPDS) that normalization 
of blood glucose substantially  decreases the frequency  of microvascular complications of T2DM
(UKPDS Group 1998), consistent with what has been noted with ty pe 1 diabetes.10It is assumed 
that a management regimen based on adequate glycemic control, via lifesty le changes with 
modification of diet and physical activity  and, as appropriate, medical treatment, should help to 
reduce the risk of complications in y ounger persons as well as adults with the disease.
Current therapeutic agents have limite d efficacy  and are associated with side effects including 
hypoglycemia, weight gain, edema and gastrointestinal effects. While there are several oral 
glucose lowering medications approved for adults with T2DM , the only oral glucose lowering 
Clinical Protocol MB102138
BMS -512148 dapagliflozin
Revised Protocol No: 03
Date: 20-Sep- 2017 14medication appr oved for use in pediatric patients age 10 and older is metformin. Agents with new 
mechanisms of action for the treatment of T2DM are being studied.
Given the need for additional oral glucose lowering therap y options for pediatric patients with 
T2DM , it is appropriate to test the hypothesis that dapagliflozin, an orally  active sodium glucose 
cotransporter -2 (SGLT -2)inhibitor, will confer the therapeutic benefits of glucose -lowering and 
some weight loss, without adding the risk of hy poglycemia, in this population. This program will 
investigate the efficacy , safet y, and tolerabilit y of dapagliflozin versus placebo for the treatment 
of patients with pediatric or earl y age onset T2DM .
1.1 Study Rationale
This protocol will be performed to meet the requirements of the European Union (EU) Pediatric 
Investigations Plan (PIP) for Type 2 Diabetes, and aims to allow for the extended use of 
dapagliflozin in appropriate pediatric patients. 
Dapagliflozin has been shown to be effective in lowering HbA1c in adult patients with T2DM, 
when studied as monotherap y and in combination with insulin or oral antidiabetic (OAD) 
medications. Overall, through its development program, dapagliflozin has been shown to improve 
HbA1c with a low risk of hypoglycemia, while also demonstrating positive trends for common 
comorbidities (weight gain and systolic hypertension) associated with increased cardiovascular 
risk in T2DM adult patients.
A number of studies have demonstrated that the rising prevalence of T2DM in pediatric patients 
parallels thegrowing obesity  problem in this population as it does in adults.9,11,12However, studies 
from German y, the United Kingdom (UK), and Sweden indicate that T2DM remains a rarity 
among children in Europe.13,14,15Also, the recruitment of pediatric patients with T2DM into 
clinical trials has proven very  difficult for a number of reasons. Innovative methods are therefore 
required to ensure that new novel treatments, such as dapagliflozin, are studied and made available 
to this population. 
Given the anticipated challenges to recruitment with this population, a partial extrapolation 
approach was used to better inform the sample size determination. Full extrapolation was not 
pursued because the criteria for full 
extrapolation were deemed not to have been met for this 
disease. This partial extrapolation approach entails that the pediatric outcom e and design is 
informed b y extrapolation from adult data, and the actual data from the trial proposed will be used 
to validate the extrapolation.
A probability  estimate was determined using clinical trial simulation from a non-linear mixed 
effects model for the relationship between dapagliflozin pharmacokinetics (PK) and HbA1c 
response in adult T2DM subjects. Adjustments were made to the model for expected differences 
in the covariate effects on PKandpharmacodynamic (PD)parameters due to the differences in 
baseline characteristics between adult and pediatric T2DM subjects. The 
simulation allowed for 
the sample size to be reduced, while maintaining 85% probability  of demonstrating superiority  to 
placebo for dapagliflozin 10 mg. 
Clinical Protocol MB102138
BMS -512148 dapagliflozin
Revised Protocol No: 03
Date: 20-Sep- 2017 151.2 Research Hy pothesis 
Dapagliflozin results in a greater mean reduction from baseline in HbA1c compared to placebo 
after 24 weeks of double -blind add-ontreatment in patients aged 10 to less than 25 years with 
T2DM who have inadequate glycemic contr ol on diet and exercise with metformin or insulin 
metformin.
1.3 Objectives (s)
1.3.1 Primary Objectives
To compare the mean change from baseline in HbA1c achieved with dapagliflozin against the 
mean achieved with placebo after 24 weeks of double -blind add- ontreatment in patients aged 10to 
less than 25 years with T2DM who have inadequate glycemic control on diet and exercise with 
metformin or insulin  metformin.
1.3.2 Secondary Objectives
To compare the mean change from baseline in Fasting Plasma Glucose (FPG) achieved with 
dapagliflozin against the mean achieved with placebo after 24 weeks of double -blind add-on 
treatment in patients aged 10 to less than 25 y ears with T2DM who have inadequate gl ycemic 
control on diet and exercise with metformin or insulin metformin .
To compare the percentage of subjects who require glycemic rescue or discontinuation due to 
lack of glycemic control with dapagliflozin against the percentage with placebo over the 
24weeks of double -blind add-on treatment in patients aged 10 to less than 25 years with T2DM 
who have inadequate glycemic control on diet and exercise with metformin, or insulin 
metformin .
To compare the percentage of subjects with baseline HbA1c >7% who achieve a HbA1c level 
< 7% with dapagliflozin against the percentage achieved with placebo after 24weeks of 
double -blind add -on treatment in patients aged 10 to less than 25 y ears with T2DM who have 
inadequate glycemic control on diet and exercise with metformin, or insulin metformin
.
1.3.3 Safety Objectives
To assess the safet y and tolerability of dapagliflozin as add -on treatment in patients aged 10 to 
less than 25 years with T2DM who have inadequate glycemic control on diet and exercise with 
metformin or insulin metformin when administered for up to 24 weeks of short -term therap y 
and 52 weeks of total therap y.
To assess the percentage of subjects who experience hypogly cemia with dapagliflozin against 
the percentage achieved with placebo as add-on treatment in patients aged 10toless than 
25years with T2DM who have inadequate glycemic control on diet and exercise with 
metformin, or insulin  metformin when administered for up to 24 weeks.
To assess markers of growth and maturation, the incidence of diabetic ketoacidosis (DKA) , 
and changes in markers of bone health with dapagliflozin against tho se observed with placebo 
as add -on treatment in patients aged 10 to less than 25 years with T2DM who have inadequate 
glycemic control on diet and exercise with metformi n or insulin metformin when 
administered for up to 24 weeks.
Clinical Protocol MB102138
BMS -512148 dapagliflozin
Revised Protocol No: 03
Date: 20-Sep- 2017 161.3.4 Exploratory Objectives
To explore the PK and exposure -response relationship of dapagliflozin in patients aged 10 to 
less than 25 y ears with T2DM based on the collection of population PK samples.
To explore the mean change from baseline in HbA1c achieved with dapagliflozin after 
52weeks of add-ontreatment in patients aged 10 to less than 25 years with T2DM who have 
inadequate glycemic control on diet and exercise with metformin or insulin metformin.
To explore the mean change from baseline in FPG achieved with dapagliflozin after 52 weeks 
of add-ontreatment in patients aged 10 to less than 25 years with T2DM who have inadequate 
glycemic control on diet and exercise with metformin or insulin metformin.
To explore the percentage of subjects who require glycemic rescue or discontinuation due to 
lack of gl ycemic control with dapagli flozin over the 52 weeks of add -on treatment in patients 
aged 10 to less than 25 years with T2DM who have inadequat e glycemic control on diet and 
exercise with metformin or insulin metformin .
To explore the percentage of subjects with baseline HbA1c 7% who achieve a HbA1c level 
<7% with dapagliflozin after 52 weeks of add-ontreatment in patients aged 10 to less than 
25years with T2DM who have inadequate glycemic control on diet and exercise with 
metformin or insulin  metformin.
1.4 Product Development Background
Dapagliflozin is a rationally  designed, stable, competitive, reversible, highly  selective and orally 
active inhibitor of SGLT -2, the major transporter responsible for renal glucose reabsorption. 
Dapagliflozin inhibits human SGL T-2 (Ki = 0.55 nM) selectivel y (1400- fold selective), and is also 
highl y selective vs. other f acilitative glucose transporters. Dapagliflozin’s mechanism of action is 
different and complementary  to the mechanisms of currently  available medicines, resulting in the 
direct and insulin -independent elimination of glucose by the kidney. Further, as SGLT -2 is almost 
exclusively  expressed in the kidney , the highl y selective nature of dapagliflozin minimizes the risk 
of off target (i.e.
, non- kidney ) effects. As such, dapagliflozin offers an important additional 
strategy  for improving glycemic control in patients with T2DM.
Dapagliflozin has been shown to be effective in lowering HbA1c in adult patients with T2DM, 
when studied as monotherapy and in combination with insulin or OAD medications. Results from 
secondary  glycemic efficacy  endpoints (including FPG, 2-hour postprandial glucose [PPG], and 
change in HbA1c in patients with baseline HbA1c 9.0%) are consistent with the main HbA1c 
results and further support the role of dapagliflozin as a glucose lowering agent. Importantl y, 
dapagliflozin has been shown toimprove glycemic control with a low intrinsic risk for 
hypoglycemia . Furthermore, the stead y excretion of glucose due to SGLT -2 inhibition results in a 
continual loss of calories that ultimately  leads to a decrease in weight and adiposity . The inhibition 
of sodium and glucose transport in the proximal tubule also causes a mild diuretic effect, leading 
to a modest lowering of blood pressure (BP) . Overall, dapagliflozin has been shown to improve 
HbA1c with a low 
risk of hypoglycemia , while also demonstrating positive trends for common 
comorbidities (weight gain and systolic hypertension) associated with increased cardiovascular 
risk in T2DM adult patients.
Clinical Protocol MB102138
BMS -512148 dapagliflozin
Revised Protocol No: 03
Date: 20-Sep- 2017 171.5 Overall Risk/Benefit A ssessment
Dapagliflozin is approved for use in adults in approximately  40 countrie s including the United 
States (US)andEU. Prior to approval, dapagliflozin was evaluated in 5 core Phase 2b studies, 
16core Phase 3 studies, and 3 regional Phase 3 studies. These studies established that dapagliflozin 
is effective in reducing HbA1c in a broad range of adult subjects, regardless of disease 
progression/duration or concomitant use of antidiabetic therapies. Dapagliflozi n consistently  
demonstrated statistically  and clinicall y significant mean reductions in HbA1c versus placebo 
among the three doses typically  studied (2.5, 5, and 10 mg). Overall, the dose of 10 mg provided 
better efficacy  than the two lower doses. Effects on secondary  glycemic efficacy  parameters, 
including FPG and PPG, support the primary  HbA1c efficacy  findings. Dapagliflozin also resulted 
in a modest reduction in total body  weight relative to placebo or comparator, largely  attributable 
to a decrease in b ody fat mass, as well as reductions in sy stolic BP. Placebo- controlled data for up 
to 2years indicate that the beneficial effects on glycemic and non-glycemic parameters were 
maintained.
Overall, dapagliflozin has been well tolerated in clinical studies.
For an overall risk/benefit assessment of dapagliflozin, see the I nvestigator’s Brochure (IB).
2 ETHICA L CONSIDERA TIONS
2.1 Good Clinical Practice
This study  will be conducted in accordance with Good Clinical Practice (GCP), as defined by  the 
International Confe rence on Harmonisation (ICH) and in accordance with the ethical principles 
underly ing EU Directive 2001/20/EC and the US Code of Federal 
Regulations, Title 21, 
Part50(21CFR50).
The study  will be conducted in compliance with the protocol. The protocol andany amendments 
and the subject informed consent will receive Institutional Review Board/I ndependent Ethics 
Committee (I RB/IEC) approval/favorable opinion prior to initiation of the study .
All potential serious breaches must be reported to the Sponsor or designee immediately . A serious 
breach is a breach of the conditions and principles of GCP in connection with the study  or the 
protocol, which is likely  to affect, to a significant degree, the safet y or ph ysical or mental integrity 
of the subjects of the st udy or the scientific value of the study .
Personnel involved in conducting this study  will be qualified by education, training, and 
experience t o perform their respective tasks.
This study  will not use the services of study  personnel where sanctions have been invoked or where 
there has been scientific misconduct or fraud ( e.g., loss of medical licensure, debarment).
2.2 Institutional Review  Board/Independent Ethics Committee 
Before study  initiation, the Investigator must have written and dated approval/favorable opinion 
from the IRB/IEC for the protocol, consent form, subject recruitment material s 
(e.g., advertisements), and any other written information to be provided to subje cts. The 
Clinical Protocol MB102138
BMS -512148 dapagliflozin
Revised Protocol No: 03
Date: 20-Sep- 2017 18Investigator or Sponsor (or designee) should also provide the IRB/IEC with a copy of the IBor 
product labeling information to be provid ed to subjects and an y updates.
The Investigator or Sponsor (or designee) should provide the IRB/IEC with reports, updates and 
other information (e.g.,expedited safety  reports, amendments, and administrative letters ) 
according to regulatory  requirements or institution procedures.
2.3 Informed Consent
Investigators must ensure that subjects are clearl y and fully  informed about the purpose, potential 
risks, a nd other critical issues regarding clinical studies in which they  volunteer to pa rticipate.
In situations where consent cannot be given to subjects, their legally  acceptable representatives (as 
per country  guidelines) are clearl y and full y informed about the purpose, potential risks, and other 
critical issues regarding clinical studies in which the subject volunteers to participate.
Sponsor or designee will provide the Investigator with an appropriate (i.e., Global or Local) sample 
informed consent form (ICF) which will include all elements required by ICH, GCP and applicable 
regulatory  requirements. The sample ICFwill adhere to the ethical principles that have their origin 
in the Declaration of Helsinki.
Investigators must:
1)Provide a copy  of the consent form and written information about the study  in the language in 
which the subject is proficient prior to clinical study  participation. The language must be 
non-t echnical and easil y understood.
2)Allow time necessary for su bject or subject's legally acceptable representative to inquire about 
the details of the study .
3)Obtain an informed consent signed and personally dated b y the subject or the subject's legall y 
acceptable representative and by  the person who conducted the inf ormed consent discussion. 
4)Obtain the IRB/IEC’s written approval/favorable opinion of the written ICF and any other 
information to be provided to the subjects, prior to the beginning of the study , and after any 
revisions are completed for new information.
5)If informed consent is initially  given by a
 subject’s legall y acceptable representative or legal 
guardian, and the subject subsequently becomes capable of making and co mmunicating his or 
herinformed consent during the study , consent must additionally  be obtained from the subject.
6)Revise the informed consent whenever important new information becomes available that is 
relevant to the subject's consent. The Investigator , or a person designated by  the Investigator , 
should fully inform the subject or the subje ct's legall y acceptable 
representative or legal 
guardian, of all pertinent aspects of the study  and of any new information relevant to the 
subject's willingness to continue participation in the study . This communication should be 
documented.
The confidenti ality of records that could identify  subjects must be protected, respecting the privacy 
and confidentiality  rules applicable to regulatory  requirements, the subjects' signed ICF and, in the 
US, the subjects’ signed Health Insurance Portability  and Accounta bility Act of 1996 ( HIPAA )
Authorization.
Clinical Protocol MB102138
BMS -512148 dapagliflozin
Revised Protocol No: 03
Date: 20-Sep- 2017 19The consent form must also include a statement that the Sponsor or designee and regulatory 
authorities have di rect access to subject records.
For minors, according to local legislation, one or both parents or a legall y acceptable representative 
must be informed of the study  procedures and must sign the ICFapproved for the study  prior to 
clinical study  participation. The explicit wish of a minor ,who is capable of forming an opinion 
and assessing this information, to refuse participation in, or to be withdrawn from, the clinical 
study  at an y time should be considered b y the Investigator .
Minors who are judged to be of an age of reason must also give their written assent.
Subjects unable to give their writte n consent may only  be enrolled in the study with the consent of 
a legall y acceptable representative. The subject must also be informed about the nature of the study 
to the ext ent compatible with his or her understanding, and should this subject become capable, he 
or she should personall y sign and date the consent form as soon as possible. The explicit wish of 
a subject who is unable to give his or herwritten consent, but who is capable of forming an opinion 
and assessing information to refuse participation in, or to be withdrawn from, the clinical study  at 
any time should be considered by  the Investigator .
The rights, safet y, and well -being of the study  subjects are the most important considerati ons and 
should prevail over interests of science and society.
3 INVESTIGA TIONA L PLA N
3.1 Study Design and Duration
The study  will be a prospective, multi- center, 24-week, placebo controlled, double -blind 
randomized study  with a 28-week open -label safety  extension. Subjects 10 years and < 25years 
of age, with confirmed diagnosis of T2DM ,who are being treated with diet and exercise and a 
stable dose of metformin 
immediate release ( IR)or extended release ( XR)(at least 1000 mg daily) 
for a minimum of 8 weeks prior to screening, or a stable dose of insulin for a minimum of 8 weeks 
prior to screening, or a stable combination of metformin and insulin for a minimum of 8 weeks 
prior to screening, will be screened against the inclusion and exclusion criteria, as per Section 3.3. 
Eligible subjects meeting all criteria will enter a 4
-week placebo lead-in perio d. Subjects will be 
instructed to follow a diet and exercise program (in accordance with the American Diabetes 
Association [ADA] or similar national guidelines) for the duration of the study . Subjects will 
maintain their baseline t ypes of antidiabetic ther apy throughout the study . 
Recruitment (randomization) of subjects 18 and < 25 years old will be limited to<40% of 
subjects. Recruitment (randomization) of subjects 10 and 15 years old will include at least 
20% of subjects. 
After the lead-in perio d, at least 66 subjects with HbA1c 6.5% and 11% at screening will be 
randomized 1:1 to receive oral blinded dapagliflozin 10 mg or placebo, stratified by gender, age 
(<18 vs. 18 years and ≤ 15 years vs. >15 to < 18 years) and baseline medication (metformin 
alone, insulin metformin). After completion of the 24-week short -term treatment period, all 
subjects will enter the 28-week open -label safety  extension period for safet y monitoring. All 
subjects will receive dapag liflozin 10 mg for the duration of this period. This will be followed by  
Clinical Protocol MB102138
BMS -512148 dapagliflozin
Revised Protocol No: 03
Date: 20-Sep-2017 20a 4-week post-treatment safet y follow -up period. The study  will end when all evaluable subjects 
complete the 56 weeks of study .
Subjects who discontinue study  drug before 
the end of the study  treatment period will enter a 
non-treatment, follow -up phase, in which subjects will follow their visit schedules with modified 
assessments until study  completion. Discontinued subjects will not be replaced. 
Glycemic rescue parameters are include d for subjects who meet the criteria for lack of glycemic
control in both the 24- week short -term treatment period and the 28 -week safety extension period. 
Investigators will use insulin as rescue. Rescued subjects will continue treatment on study  drug.
Safety measures will be collected throughout the study . This will include regular self-monitored 
blood glucose (SMBG) levels, self -monitored blood ketone levels, and monitoring of growth and 
development. 
Population PK samples will be collected pre -dose and a pproximately  2 hours post-dose ( 1hour) 
during the Week 16 and 24 visits. The study  design schematic is presented in Figure 3.1 -1.
Figure 3.1 -1: Study Design Schematic
3.2 Post Study  Access to Therapy
At the end of the treatment period (at Week 52 visit) or early discontinuation, the Sponsor or 
designee will not continue to provide Sponsor supplied study  drug to subjects/investigators unless 
the Sponsor or designee chooses to extend the study . The Investigator should ensure that the 
subject receives appropriate standard of care to treat the condition under study.
3.3 Study Population
For entry  into the study , the following criteria MUST be met.
3.3.1 Inclusion Criteria
1.Signed Written Informed Consent
a)Subjects (or designee) must be willing and able to give signed and dated written informed 
consent. Minor’s parents or legally  acceptable representatives must give fully  informed 

Clinical Protocol MB102138
BMS -512148 dapagliflozin
Revised Protocol No: 03
Date: 20-Sep- 2017 21written consent. Assent should be obtained according to local regulations and if child is 
capable.
2. Target Population
a)Previously  diagnosed with T2DM by  World Health Organization ( WHO )/ADA diagnostic 
criteria
b)HbA1c 6.5% and  11% obtained at screening visit
c)Currently  on diet and exercise and a stable dose of metformin (at least 1000 mg daily ) for 
a minimum of 8 weeks, or stable dose of insulin for a minimum of 8 weeks, or a stable 
combination of metformin (at least 1000 mg dai ly) and insulin for a minimum of 8 weeks 
prior to screening
d)FPG 255 mg/dL ( 14.2 mmol/L) obtained at screening visit
e)Subject Re-enrollment: This study  permits the re-enrollment of a subject that has 
discontinued the study  as a pre-treatment failure (i.e., subject has not been randomized / 
has not been treated) .
Note: If re-enrolled, the subject must be re-consented. All screening procedures will be 
repeated. Subjects may  only  be re -enrolled once.
3.Age and Reproductive Status
a)Males and females , ages 10 years of age, up to but not including 25 years of age at the time 
of randomization. 
i)Recruitment (randomization) of subjects 18 and < 25 years old will be limited to 
<40% of subjects. 
ii)Recruitment (randomization) of subjects 10 and 15 years old will include at least
20% of subjects.
b)Women of childbearing potential (WOCBP) must have a negative serum or urine 
pregnancy  test (minimum sensitivity  25 IU/L or equivalent units of beta-human chorionic 
gonadotrophin )within 24 hours prior to the start of study  drug.
c)Women must not be breastfeeding
d)Women of childbearing potential must agree to follow instructions for method of 
contraception for the duration of treatment with study drug, plus 5 half-lives of stud y drug 
or 30 day s (whichever is longer), plus 30 day s (duration of ovulatory  cycle), for a total of 
60 day s post -treatment completion.
e)Women of childbearing potential who are continuously  not heterosexually  active are 
exempt from contraceptive requirements. However ,they must still undergo pregnancy 
testing as described in this section.
Investigators shall counsel WOCBP on the importance of pregnancy  prevention and the 
implications of an unexpected pregnancy .Investigators shall advise WOCBP on the use of highly 
effective methods of contraception. High ly effective methods of contraception have a failure rate 
of < 1% when used consistently  and correctly .
Clinical Protocol MB102138
BMS -512148 dapagliflozin
Revised Protocol No: 03
Date: 20-Sep- 2017 22At a minimum, subjects must agree to use one highl y effective OR one less effective method of 
contraception as listed below:
A.HIGHLY EFFECTIVE METHODS OF CONTRACEPTION
Highl y effective methods of contraception have a failure rate of < 1% when used consistentl y and 
correctly . Women of childbearing potential are expected to use one of the highl y effective methods 
of contraception listed below. Contraception methods are as follows:
1.Progestogen -only hormonal contraception associated with inhibition of ovulation
2.Hormonal methods of contraception including oral contraceptive pills containing 
combined estrogen + progesterone, vaginal ring, injectables, implants and intrauterine 
devices (IUDs) such as Mirena 
3.Nonhormonal IUDs, such as ParaGard 
4.Bilateral tubal occlusion
5.Vasectomised partner with documented azoospermia 90 day s after procedure
a.Vasectomised partner is a highly  effective birth control method provided that 
partner is the sole sexual partner of the WOCBP trial participant and that the 
vasectomised partner has received medical assessment of the surgical success.
6.Intrauterine hormone -releasing s ystem
7.Complete abstinence
a.Complete abstinence is defined as the complete avoidance of heterosexual 
intercourse (refer to Glossary  of Terms) .
b.Complete abstinence is an acceptable form of contraception for all study drugs and 
must be used throughout the duration of the study  treatment (plus 5 half-lives of the 
investig ational drug plus 30 day s).
c.It is not necessary  to use any other method of contraception when complete 
abstinence is elected.
d.Subjects who choose complete abstinence must continue to have pregnancy tests. 
e.Acceptable alternate methods of highl y effective contraception must be discussed 
in the event that the subject chooses to forego complete abstinence.
f.The reliability of sexual abstinence needs to be evaluated in relation to the duration 
of the clinical trial and the preferred and usual lifesty le of the subject.
B.LESS EFFECTIVE METHODS OF CONTRACEPTION
1. Diaphragm with spermicide
2.Cervical cap with spermicide
3. Vaginal sponge with spermicide
4.Male or female condom with or without spermicide .16,17A male and a female condom must 
not be used together .
5.Progestogen -
only oral hormonal contraception, where inhibition of ovulation isnot the 
primary  mode of action
Clinical Protocol MB102138
BMS -512148 dapagliflozin
Revised Protocol No: 03
Date: 20-Sep- 2017 23C.UNACCEPTABLE METHODS OF CONTRACEPTION
a)Periodic abstinence (calendar, s ymptothermal, post -ovulation methods)
b) Withdrawal (coitus interruptus)
c)Spermicide only
d) L actation amenorrhea method
3.3.2 Exclusion Criteria
1.Target Disease Exceptions
a)Previous diagnosis of Type 1 diabetes
b)Previous diagnosis of monogenic etiology of T2DM such as maturity onset diabetes of the 
young(MODY), genetic disorders with strong associations with insulin resistance/diabetes 
and/or obesity  such as Turner’s Syndrome and Prader -Willi, or secondary  diabetes (steroid 
use, Cushing’s disease, acromegal y)
c)Diabet icketoacidosis within 6 months of scre ening
d)Current use of the following medications for the treatment of diabetes, or use within the 
specified timeframe prior to screening for the main study :
i)Eight weeks: sulfony lureas, alpha glucosidase inhibitors, metiglinide, oral or injectable 
incretins or incretin mimetics or other antidiabetes medications not otherwise specified
ii)Sixteen weeks: thiazolidinediones
iii)Any previous history  or current use of an SGLT -2 inhibitor, including dapagliflozin
e)Initiation or discontinuation of prescription or non-prescri ption weight loss drugs within 
8weeks of screening. Use of prescription or non-prescription weight loss drugs must be 
stable during the study .
2.Medical History and Concurrent Diseases
a)Pregnant, positive serum pregnancy  test, planning to become pregnant during the clinical 
trials, or breastfeeding
b)History  of unstable or rapidly  progressive renal disease
c)History  of unresolved v esico -ureteral reflux
d)History  of hemoglobinopathy , with the exception of sickle cell trait or thalassemia minor; 
or chronic or recurre nt hemoly sis
e)Malignancy  within 5 years of the screening visit (with the exception of treated basal cell 
or treated squamous cell carcinoma)
f)Significant co-morbidit y that, in the opinion of the investigators, will increase the risk to 
the subject such as coronary artery disease, an y heart disease that increases risk associated 
with exercise, orimmune -suppression
g)Replacement or chronic systemic corticosteroid therap y, defined as any dose of systemic 
corticosteroid taken for > 4 weeks within 3 month s prior to the Day  1 visit
NOTE: Topical, nasal, or inhaled corticosteroids are allowed
Clinical Protocol MB102138
BMS -512148 dapagliflozin
Revised Protocol No: 03
Date: 20-Sep- 2017 243. Physical and Laboratory Test Findings
a)Abnormal renal function, which is defined in subjects < 18 years of age as an estimated 
glomerular filtration rate (eGFR) calculated by the Schwartz Formula 
< 80 mL/min/1.73 m2(1.33 mL/s)18, and in subjects 18 years as an eGFR calculated by 
the Modified Diet in Renal Disease ( MDRD )Formula < 60 mL/min/1.73 m2(1.33 mL/s)19
b)Presence of either: antibodies to glutamic acid decarbox ylase (GAD) or protein tyrosine 
phosphatase -like protein antibodies (IA- 2)
c)An abnormal thyroid stimulating hormone (TSH )value at screening will be further 
evaluated for free T4. Subjects with abnormal f ree T4 values will be excluded.
Note: In subjects who have had a prior diagnosis of a thyroid disorder and who are currently 
receiving thyroid replacement therapy , a one-time retest of TSH may be allowed, as 
determined by the Investigator , after a minimum of 6 weeks following the adjustment of 
thyroid hormone replacement therapy . Such cases should be discussed with the Sponsor 
prior to re-testing. The subject must have all enrollment procedures and laboratory 
assessments performed as part of this re-test, and all of these must meet enrollment 
eligibility  criteria. The subject’s number will however remain the same as initially  
assigned.
d)Hematuria (confirmed by microscop y at screening) with no explanati on as judged by the 
Investigator up to randomization. 
e)Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2× upper limits of 
normal (ULN) , or clinically  significant hepatic disease.
f)Serum total bilirubin (TB) 2x UL N, unless exclusively  caused b y Gilbert’s sy ndrome
g)History  of positive serologic evidence of current infectious liver disease including 
anti-hepatitis A virus 
(HAV) ( Immunoglobulin M [IgM]), hepatitis B surface antigen 
(HBsAg), or anti-hepatitis C virus (HCV). Patients who may have isolated positive 
hepatitis B surface antibodies may be included.
h)Anemia of any etiology  defined as hemoglobin 10.7 g/dL (107 g/L) for females and 
11.3 g/dL (113 g/L) for males. Subjects who are considered to have anemia accordi ng to 
local guidelines should be excluded.
i)Volume -depleted subjects. Subjects at risk for volume depletion due to co-existing 
conditions or concomitant medications, such as loop diuretics, should carefully monitor 
their volume status.
j)Clinically  significant abnormalities in any pre-randomization laboratory analyses or 
electrocardiogram (ECG )that, in the Investigator ’s opinion, would preclude 
randomization.
4.Allergies and Adverse Drug Reaction
a)Known allergy , sensitivity  or contraindication to any  study  drug or its excipient/vehicle.
Clinical Protocol MB102138
BMS -512148 dapagliflozin
Revised Protocol No: 03
Date: 20-Sep- 2017 255.Other Exclusion Criteria
a)Subject is currently  abusing alcohol or other drugs or has done so within the last 6 months 
prior to the screening visit.
b)Prisoners or subjects who are involuntaril y incarcerated
c)Subjects who are compulsor ily detained for treatment of either a psychiatric or physical 
(e.g., infectious disease) illness
d)Psychiatric or cognitive disorder that will, in the opinion of investigators, limit the subject’s 
ability  to comply  with the study  medications and monitoring.
e)Subjects who have contraindications to therap y as outlined in the dapagliflozin IB or local 
package inserts
f)Participation and receiving investigational product (IP)in another clinical study during the 
prior 3 months
Eligibility  criteria for this study  have been carefully  considered to ensure the safet y of the study 
subjects and that the results of the study  can be used. It is imperative that subjects fully  meet all 
eligibility  criteria.
3.3.3 Women of Childbearing Potential
A woman of childbearing potential is defined as any female who has experienced menarche and 
who has not undergone surgical sterilization (hy sterectom y or bilateral oophorectom y) and is not 
postmenopausal.
3.4 Concomitant Treatments
3.4.1 Prohibited and/or Restricted Treatments
Once consented ,subject s may not receive any prescription antihy pergl ycemic medication other 
than study  drug, metformin and/or insulin .
Once consented, subjects should not begin treatment with any  systemic corticosteroid therapy 
lasting 5 days (inhaled and topical 
are allowed) . Subjects who require systemic corticosteroid 
therap y should be discussed with the medical monitor prior to starting therap y whenever 
possible .
Once consented, subjects should not commence or modify  therap y with any prescription or 
over the counter weight loss medications.
Once consented, subjects should no t undergo an y bariatric surgery .
3.4.2 Other Restrictions and Precautions
Subjects must comply  with their prescribed dosing regimen to preserve study  integrity  and 
ensure subject safet y.
Subjects should be cautioned that any  new prescription, over -the-counter or herbal/nutritional 
therapies should be discussed thoroughl y with the Investigator as concomitant use could result 
in alterations to their glycemic control and may place them at risk for significant hypogl ycemic 
episodes .
Clinical Protocol MB102138
BMS -512148 dapagliflozin
Revised Protocol No: 03
Date: 20-Sep- 2017 26Medication other than those which are protocol prohibited as described above, considered 
necessary  for the patient’s safet y and well-being , may be given at the discretion of the 
Investigator and must be recorded in the appropriate sec tions of the case report form (CRF) .
Subjects must make every attempt to adhere to the diet and exercise counseling and to the study  
flow chart/time and ev ents schedule (see Section 5.1).
Women of childbearing 
potential must immediately  contact the Investigator if they suspect 
they might be pregnant and if they  have changed or plan to change their birth control method.
3.5 Disco ntinuation of Subjects follow ing any Treatment with Study Drug 
Subjects MUST discontinue IP(and non-investigational product [non-IP]at the discretion of the 
Investigator ) for an y of the following reasons:
Subject’s request to stop study  treatment
Any clinical adverse event (AE), laboratory  abnormality  or intercurrent illness which, in the 
opinion of the 
Investigator , indicates that continued participation in the study is not in the best 
interest of the subject
Term ination of the study  by Sponsor
Loss of abilit y to freely provide consent through imprisonment or involuntarily  incarceration 
for treatment of either a psy chiatric or ph ysical ( e.g., infectious disease) illness
Unblinding a subject for any  reason (emergency  or non -emergency )
Severe non -compliance to protocol, as judged b y the Investigator and/or Sponsor
Safety  reasons as judged by  the Investigator and/or Sponsor
Pregnancy
Subjects experiencing decreased renal function must be evaluated as per Investigator’s 
discretion. 
oSubjec t
swith eGFR < 50 mL/min/1.73 m2(by Schwarz formula18for subject s
< 18 years and by MDRD formula19for subjects 18 years) for a sustained period of 
time (12 to 16 weeks) must be discontinued.
Subjects with a central laboratory  ALT and/or AST > 3xUL N will be scheduled for a follow -up 
visit within 3 days following the receipt of the result (see Appendix 1 and Appendix 2for 
further guidance). Subjects should be discontinued from study  drug if the initial repeat 
laboratory  tests meet any of the following criteria:
oALT and/or AST are > 3x ULN and TB > 2x ULN. 
oALT and/or AST are > 5x ULN for 14 consecutive days, at any time after initial 
confirmatory  results.
oALT and/or AST are  10x ULN.
In the case of pregnancy , the Investigator must immediately  notify  the Sponsor’s Medical 
Monitor/designee of this event. The study  drug will be permanently  discontinued in an appropriate 
manner.
All subjects who discontinue study  drug should comply  with protocol -specified follow -up 
procedures as outlined in Section 5. The only exception to this requirement is when a subject 
Clinical Protocol MB102138
BMS -512148 dapagliflozin
Revised Protocol No: 03
Date: 20-Sep- 2017 27withdraws consent for all study  procedures including post -treatment study  follow -up or loses the 
ability  to consent freel y (i.e., is imprisoned or involuntarily incarcerated for the treatment of either 
a psy chiatric or ph ysical illness).
If study  drug is discontinued prior to the subject’s completion of the study , the reason for the 
discontinuation must be documented in the subject’s medical records and entered on the 
appropriate CRF page.
3.5.1 Procedures for handling patients incorrectly enrolled or randomized
Subjects who fail to meet the inclusion/exclusion criteria must not, under any circumstances, be 
enrolled or randomized. There can be no exceptions to this rule.
Subjects who are incorrectly  enrolled, but are not yet randomized, should be withdrawn from the 
study . The procedures included in the protocol for the discontinuation of such subjects must be 
followed. Study  medication should be permanently  stopped and the subject should be further 
treated according to the Investigator ’s judgment and local therap y tradition.
If a subject not meeting the study criteria is randomized in error, and if the error is identified after 
randomization, a discussion must occur between the Sponsor Medical Monitor or designee and the 
Investigator regarding whether to continue or discontinue the subject from the study drug. If 
agreement to continue in the study is reached, the subject should complete the study  unless there 
are safet y concerns or if the subject withdraws the consent. In situations in which an agreement 
cannot be reached, the subject should have the randomized therapy  stopped and be discontinued 
from the study . The procedures included in the protocol for the discontinuation of such subjects 
must be followed. The Sponsor Medical Monitor is to ensure all such contacts with the Investigator
and such decisions are appropriatel y documented. 
Withdra wn subjects will not be replaced.
3.5.2 Rescue Guidelines for Subjects with Protocol- Defined Lack of Glycemic 
Control
During the course of the trial, subjects may be eligible for the addition of open -label rescue 
medication to their blinded treatment regimen in order to treat ongoing hypergl ycemia. Insulin will 
be initiated or up -titrated as rescue .
Pre-specified glycemic criteria (see Table 3.5.2-1), based upon SMBG FPG, or single central 
laboratory  FPG and repeat confirmatory  FPG have been established during the treatment period, 
starting at Day 1, and up totheWeek 52 visit, to determine eligibility for open -label rescue 
medication. For subjects on baseline insulin, persistently  increased doses of insulin 20% or more 
above baseline dose, despite advice and counsel to keep the insulin dose stable, may be considered 
another potential manifestation of poor glycemic control, a nd should be evaluated for rescue. Any 
permanent changes in dose of basal insulin should be done after evaluation of rescue criteria, 
including both SMBG and central laboratory  FPG values. 
Clinical Protocol MB102138
BMS -512148 dapagliflozin
Revised Protocol No: 03
Date: 20-Sep- 2017 28Table 3.5.2 -1: Lack of Glycemic Control Criteria for Initiation of Rescue 
Medication
Study week Rescue criterion
From  Day 1 visit up to and 
including Week 24 visitFPG >13.3 mmol/L (240 mg/d L) based on SMBG for 3 consecutive 
days followed by a confirmatory central laboratory FPG or
Single central laboratory FPG followed by a confirmatory central 
laboratory FPG
Follow ing Week 24 visit up 
to and not including Week 
52 visitFPG >10 mmol/L (180 mg/d L) based on SMBG for 3 consecutive days 
followed by a confirmatory central laboratory FPG or
Single central laboratory FPG followed by a central laboratory FPG or
HbA1c >8.0%
Subjects must be rescued following one of these scenarios:
Subjects with a SMBG FPG value meeting the lack of glycemic control criterion at any time 
during the pre-specified study  period will be instructed to repeat FPG measurements on 
2further consecutive days. If all 3 daily  values meet the relevant lack of glycemic control 
criterion subjects should be scheduled for a follow -up visit (within 1 - 5 days) to obtain a 
central laboratory  FPG value and review of the subject’s glucose meter readings. If the central 
laboratory  FPG value meets the criterion, the subject must be rescued.
Subjects with a central laboratory  FPG value meeting the lack of gl ycemic control criterion at 
a pre-specified visit will be scheduled for a follow -up visit (within 3 - 5 days) to obtain a second 
central laboratory FPG value and review ofthe subject’s glucose meter readings. If the second 
central laboratory  FPG value also meets the criterion, the subject must be rescued.
Subjects with a central laboratory HbA1c value meeting the lack of gl ycemic control criterion 
following the pre -specified Week 24 visit must be rescued .
Subjects who meet rescue criteria must first complete the Rescue Visit procedures before receiving 
open -
label rescue medication to ensure that important trial endpoint measurements are collected.
Following completion of the Rescue Visit, rescued subjects will either initiate or up-titrate 
open -
label insulin as rescue medication. Insulin should be initia tedat the lowest starting dose and 
titrated in accordance with the approved product label in the applicable country  at the discretion 
of the Investigator, in addition to their study  medication. Additional visits for titration of rescue 
medication should be scheduled as per the Investigator ’s judgment in accordance with the 
approved product label for that country  and by  the subject’s gl ycemic response. Rescued subjects 
will then continue in the study according to their original visit schedule.
Note: Rescue medication will NOT be provided by the Sponsor in this study.
3.5.3 Discontinuation Guidelines due to Protocol- Defined Hypoglycemia 
Episodes
Subjects should not be discontinued from any treatment phase based on single episodes of 
hypoglycemia or symptoms of hypoglycemia unless clinically  indicated. The assessment of a 
Clinical Protocol MB102138
BMS -512148 dapagliflozin
Revised Protocol No: 03
Date: 20-Sep- 2017 29single finger -stick or central laboratory  glucose value should not be the sole assessment used to 
determine subject discontinuation for hypoglycemia. Clinical indications for discontinuation 
because of hy poglycemia may include the following:
Multiple occasions of episodes outlined below that, in the opinion of the Investigator , indicate 
that continued treatment with study  therap y is not in the best interest of the subject. This 
includes, but is not limited to:
oRecurrent s ymptoms suggestive of hy pogly cemia ( e.g., sweating, shakiness, increased 
heart rate(HR) , confusion, dizziness, light-headedness, or hunger) in the absence of 
environmental factors known to contribute to hypogly cemia (i.e., excess physical 
activity , concurrent illness, or missed or delay ed meal).
oRecurrent documented capillary  or plasma blood glucose values < 54 mg/dL 
(<3.0mmol/L ).
A subject may also be discontinued from the study  because of severe hypoglycemia as 
determined b y the Investigator .
Down -titration of blinded study drug and/or background antihyper glycemic agent during 
the study
Down -titration of blinded study  drug and/or background metformin will not be allowed at any time 
during the stud y.
Subjects on background insulin treatment who experience multiple or severe episodes of 
hypoglycemia may down-titrate insulin treatment during the study . The down -titration should be 
minimized, but is at the Investigator ’s discretion.
3.5.4 Discontinuation Guidelines due to Diabetic Ketoacidos is (DKA)
There have been post-marketing reports of ketoacidosis, including DKA, inpatients with type 1 
and T2DM taking dapagliflozin and other SGLT -2inhibitors, although a causal relationship has 
not been established. 
Patients treated with dapagliflozin who present with signs and symptoms consistent with
ketoacidosis, including nausea, vomiting, abdominal pain, malaise, and shortness of breath, should 
be assessed for ketoacidosis, even if blood glucose levels are below 14mmol/L (250 mg/dL). 
A subject with any  symptoms that may  be consistent with an event of DKA should measure blood 
ketone levels, using the provided ketone and glucose meter, interrupt study  drug and contact the 
Investigator . Treatment with the study  drug may resume when the symptoms resolve or at the 
Investigator ’s discretion. In the case of an established DKA, study  drug should be interrupted until 
the event has resolved.
Predisposing factors to ketoacidosis include a low beta-cell function reserve resulting from
pancreatic disorders (e.g., type 1 diabetes, history of pancreatitis, or pancreatic surgery ), insulin
dose reduction, reduced caloric intake, or increased insulin requirements due to infections, illness 
or surgery  and alcohol abuse.
Clinical Protocol MB102138
BMS -512148 dapagliflozin
Revised Protocol No: 03
Date: 20-Sep- 2017 303.6 Post Study  Drug Study  Follow -up
In this study , safet y is a key endpoint of the study . Post study  follow -up is of critical importance 
and is essential to preserving subject safet y and the integrit y of the study . Subjects who discontinue 
study  drug must continue to be followed for collection of outcome a nd/or survival follow -up data 
as required and in line with Section 5until death or the conclusion of the study .
Please note that afte r the discontinuation of study  drug, the management of the subject’s diabetes 
will be under the care and direction of the Investigator . 
The only exception to any of these follow -up methods is when a subject withdraws consent for all 
study  procedures, including post-treatment study  follow -up or loses the ability  to consent freely 
(i.e., is imprisoned or involuntarily  incarcerated for the treatment of either a psychiatric or physical 
illness).
3.6.1 Withdrawal of Consent
Subjects who request to discontinue study  drug will remain in the study  and must continue to be 
followed for protocol -
specified follow -up procedures. The only exception to this is when a subject 
specificall y withdraws consent for any further contact with him/her or persons previously 
authorized by subject to provide this informati on. Subjects should notify  the Investigator of the 
decision to withdraw consent from future follow -up in writing , whenever possible. The 
withdrawal of consent should be explained in detail in the medical records by  the Investigator , as 
to whether the withdrawal is from further treatment with study  drug only or also from study  
procedures and/or post-treatment study  follow -up, and entered on the appropriate CRF page. In 
the event that vital status (whether the subject is alive or dead) is being measured, publicly  
available information should be used to determine vital status only as appropriatel y directed in 
accordance with local law.
Withdrawal of Informed Consent for donated biological samples 
If a subject withdraws consent to the use of donated biological samples, the samples will be 
destroy ed, and the action documented. If samples are alread y analyzed,the Sponsor is not obliged 
to destroy  the results of this research.
The Investigator must en sure:
Subject ’s withdrawal of informed consent to the use of donated samples is notified 
immediately  to the Sponsor .
Biological samples from that subject, if stored at the study  site, are immediatel y identified, 
destroy ed, and the action documented .
The laboratory  holding the samples is informed about the withdrawn consent immediately and 
that samples are destro yed, and the action documented .
The subject and Sponsor are inf ormed about the sample disposal .
3.6.2 Lost to Follow -Up
All reasonable efforts must be made to locate subjects to determine and report their ongoing status. 
This includes follow -up with persons authorized by  the subjec t as noted above. Lost to follow -up 
Clinical Protocol MB102138
BMS -512148 dapagliflozin
Revised Protocol No: 03
Date: 20-Sep- 2017 31is defined by  the inability  to reach the subject after a minimum of three documented phone calls, 
faxes, or emails as well as lack of response by subject to one registered mail letter. All attempts 
should be documented in the subject’s medical records. If it is determined that the subject has died, 
the site will use permissible local methods to o btain the date and cause of death.
If the Investigator ’s use of a third- party representative to assist in the follow -up portion of the 
study  has been included in the subjec t’s informed consent, then the Investigator may use a 
Sponsor -retained third- party  representative to assist site staff with obtaining thesubject’s contact 
information or other vital status data necessary  to complete the follow -up portion of the study .The 
site staff and representative will conduct searches in a legall y permissible manner that may include 
public records and database research, social media research and genealogical research. Physical 
research of local municipal resources, as allowed by local laws and regulations, may be conducted.
If after all attempts, the subject remains lost to follow -up, then the last known alive date as 
determined by the Investigator should be reported and documented in the subject’s medical 
records.
3.6.3 Survey of Subject Vital Status
Subjects who prematurely  discontinue from the study  may be contacted after discontinuation from 
the study  to collect vital status and safet y information.
Clinical Protocol MB102138
BMS -512148 dapagliflozin
Revised Protocol No: 03
Date: 20-Sep- 2017 324 STUDY DRUG
Study  drug include sboth Investigational [Medicinal] Product (IP/IMP) and Non-investigational [ Medicinal ] Product (Non-IP/
Non-IMP) and can consist of the following:
Table 4 -1: Study Drugs for MB102138 : Product Description: Short -term Double -Blind 
Treatment and Long- term Open Label Treatment Period
Product Description / 
Class and Dosage FormPotencyIP/
Non-IMPBlinded or 
Open LabelManufacturerStorage Conditions
(per label)
Dapagliflozin Film Coated 
Tablet10 mg IP Blinded AstraZenecaStorage conditions (per label), 
printed on IP bottles
Placebo for Dapagliflozin 
Film Coated Tablets0 mg IP Blinded AstraZenecaStorage conditions (per label), 
printed on IP bottles
Dapagliflozin Film Coated 
Tablet10 mg IP Open -Label AstraZenecaStorage conditions (per label), 
printed on IP bottles
Clinical Protocol MB102138
BMS -512148 dapagliflozin
Revised Protocol No: 03
Date: 20-Sep- 2017 334.1 Investigational Product
An IPalso known as investigational medicinal product (IMP) in some regions, is defined a 
pharmaceutical form of an active substance or placebo being tested or used as a reference in a 
clinical study , including products alread y with a marketing authorization but used or assembled 
(formulated or packaged) different ly than the authorized form, or used for an unauthorized 
indication, or when used to gain further information about the authorized form.
The IPshould be stored in a secure area according to local regulations. It is the responsibility  of 
the Investigator to ensure that IPis only dispensed to study  subjects. The IPmust be dispensed 
only from official study  sites by  authorized personnel according to local regulations.
In this protocol, the IPis dapagliflozin 10 mg and placebo (also described inTable 4-1). 
B
ackground therapy  metformin and/or insulin (as appropriate) will not be provided by the Sponsor, 
since it is part of patients’ standard of care prior to enroll ment.
Dapagliflozin 10 mg and corresponding placebo tablets may contain lactose, which may cause 
discomfort in lactose -intolerant individuals.
Labeling : Labels will be prepared in accordance with Good Manufacturing Practice (GMP) and 
local regulatory  guidelines. The labels will fulfill GMP Annex 13 requirements for labeling. Label 
text will be translated into local language according to the regional regulatory  requirements.
4.2 Non- investigational Product
Other medications used as support or escape medication for preventative, diagnostic, or therapeutic 
reasons, as components of the standard of care for a given diagnosis, may beconsidered as non-IPs. 
Subjects are expected to be on 
background medication ofmetformin IR or XR and / or insulin. 
Insulin, as per local labeling and standard of care, will be used for rescue as described in 
Section 3.5.2.
4.3 Storage and Dispensing
The product storage manager should ensure that the study  drug is stored in accordance with the 
environmental conditions (temperature, light, and humidity ) as determined by the Sponsor or 
designee. If concerns regarding the quality  or appearance of the study  drug arise, the study  drug 
should not be dispensed and the sponsor or designee should be contacted immediately . All study 
drugs should be kept in a secure place under appropriate storage conditions. The IP label on the 
bottle specifi es the appropriate storage.
Study  drug not supplied by the Sponsor or designee will be stored in accordance with the package 
insert.
Investigational product documentation (whether supplied by the Sponsor or not) must be 
maintained that includes all process es required to ensure drug is accurately  administered. This 
includes documentation of drug storage, administration and, as applicable, storage temperatures, 
reconstitution, and use of required processes ( e.g., required diluents, administration sets).
Clinical Protocol MB102138
BMS -512148 dapagliflozin
Revised Protocol No: 03
Date: 20-Sep- 2017 344.4 Method of Assigning Subject Identification
At the screening visit each subject will be assigned a unique sequential subject number by the 
Interactive Web / Voice Response System (IWRS). This number will be used for identification 
throughout the stud y and will not be used for an y other participant.
Randomized schedules will be generated and kept by the Sponsor or designee. Subjects will be 
randomly  assigned to 1 of 2 blinded treatment groups by  the I WRS in a 1:1 ratio. Randomization 
will be stratified by gender, age (< 18 vs. 18 years and 15 years vs. > 15 to < 18 years) and 
basel ine medication (metformin alone vs. insulin metformin).
Subjects entering the 4 -week placebo lead -in period
Following completion of the Screening activities, subjects who meet all the inclusion and none of 
the exclusion criteria will be registered by the IWRS into the lead-in period, and receive blinded 
placebo treatment.
Subjects entering the 24- week double -blinded short -term treatment period
Following completion of the placebo Lead -In period, subjects who meet the criteria will be 
randomly  assigned by the IWRS at the Day 1 Randomization visit,to one of the following two 
double -blind treatment arms in a 1:1 ratio:
Blinded dapagliflozin 10 mg
Blinded placebo to match dapagliflozin 10 mg
Subjects entering the 28- week long -term extension period
Following completion of the 24-week double -blinded treatment period, subjects will enter the 
long-term open -label treatment period. All subjects will receive open -label dapagliflozin 10mg, 
i.e., s ubjects that were assigned to be on the blinded dapagliflozin 10 mg arm will receive 
open -label dapagliflozin 10 mg and s ubjects that were assigned to be on the blinded placebo arm 
will receive open -label dapagliflozin 10 mg. 
At all study  visits when study  drug is dispensed, each subject will be assigned one or several Kit 
ID numbers by  the I WRS. Kit ID numbers will be assigned non -sequentially  and will correspond 
to the numbers printed on the bottles containing study  drug, and will be recorded on the appropriate 
electronic case report form (eCRF ). The IWRS will be available 24 hours per day , 7 day s a week.
4.5 Selection and Timing of Dose for Each Subject
Subjects successfull y completing the lead-in period andmeeting all eligibility  criteria will be 
randomized (1:1) to receive either dapagliflo zin 10mg or placebo for the 24 -week double -blinded 
short -term treatment period. All subjects completing the 24-week double -blind treatment period 
will then receive open -label dapagliflozin 10 mg for the subsequent 28 -week long -term extensio n 
period.
Dapagliflozin 10 mg tablets or matching placebo 
tablets, will be administered orally  once daily for 
the duration of the stud y.
Clinical Protocol MB102138
BMS -512148 dapagliflozin
Revised Protocol No: 03
Date: 20-Sep- 2017 354.6 Blinding/Unblinding
Blinding of treatment assignment is critical to the in tegrit y of this clinical study .
Methods used to ensure blinding include: 
Investigational product will be labeled using a unique material kit ID, which is linked to the 
randomization code
The I WRS will assign the bottle of study  material to be dispensed to each patient
This is a double -blind study  wherein each patient will receive either the active drug or matching 
placebo. The active drug and placebo tablets will be identical and presented in identical 
packaging to en sure blinding of the medication
However, in the event of a medical emergency  or pregnancy  in an individual subject in which 
knowledge of the IPis critical to the subject's management, the blind for that subject may be broken 
by the Investigator . The subject’s safet y takes priority  over any other considerations in determining 
if a treatment assignm ent should be unblinded.
Before breaking the blind of an individual subject's treatment, the Investigator should determine 
that the unblinded information is necessary , i.e., that it will alter the subject's immediate 
management. In many cases, particularly  when the emergency  is clearly  not related to the IP, the 
problem may be properly  managed by assuming that the subject is receiving active product. It is 
highl y desirable t hat the decision to unblind treatment assignment be discussed with the Medical 
Monitor, but the Investigator alway s has ultimate authority  for the decision to unblind. The 
Principal Investigator should only call in for emergency  unblinding AFTER the decisi on to 
discontinue the subject has been made.
For this study , the method of unblinding for emergency  purposes is via the I WRS .
Any request to unblind a subject for non-emergency  purposes should be discussed with the 
Medical Monitor .
The exception is for tho se personnel anal yzing the PK data, the AstraZeneca Supply  Chain Study 
Management (SCSM) team and the responsible personnel carrying out the packaging and labeling 
of IPs. The randomization information will be provided to ensure appropriate treatment alloc ation 
and that only  PK samples from patients who were on the active study  treatment are anal yzed.
4.7 Treatment Compliance
Each time study  medication is dispensed, compliance will be reinforced. When study  medication 
is returned, compliance will be assessed ba sed upon subject’s interview and a count of the tablets 
returned. Compliance should be between 70% and 130% of that prescribed. The Investigator
(or designee) will record the amounts of study  medication dispensed and returned at each visit, as 
well as document reasons for non-compliance in the source document. The dates of all study 
medication dosing, including interruptions, missed doses or overd ose, must be recorded on the 
eCRF.
Clinical Protocol MB102138
BMS -512148 dapagliflozin
Revised Protocol No: 03
Date: 20-Sep- 2017 36If the subject is not 70% compliant with study  drug doses during the study , then the period of 
non-compliance should be noted as a significant protocol deviation and the sponsor should be 
notified. The subject should be re-educated regarding the importance of study  drug compliance.
4.8 Destruction of Study  Drug
For this study , study  drugs (those supplied by  the Sponsor or sourced by  the Investigator ) such as 
partially  used study  drug containers, vials and syringes are to be destroy ed locally  at a site 
approved b y the local regulatory authority in accordance with local regulations. 
Any unused study  drugs can only be destro yed after being inspected and reconciled by the 
responsible Study  Monitor unless study  drug containers must be immediatel y destroy ed as required 
for safety , or to meet local regulations ( e.g., cytotoxics or biologics). 
On-site destruction is allowed provided the following minimal standards are met:
On-site disposal practices must not expos e humans to risks f rom the drug .
On-site 
disposal practices and procedures are in agreement with applicable laws and 
regulations, including any  special requirements for controlled or hazardous substances.
Written procedures for on-site disposal are available and followe d. The procedures must be 
filed with the site’s standard operating procedures and a copy provided to the Sponsor/ designee
upon request .
Records are maintained that allow for traceability  of each container, including the date 
disposed of, quantity  disposed, and identification of the person disposing the containers. The 
method of disposal, i.e., incinerator, licensed sanitary  landfill, or licensed waste disposal 
vendor must be documented .
Accountability  and disposal records are complete, up -to-date, and available for the Monitor to 
review throu ghout the clinical trial period .
If conditions for destruction cannot be met,the responsible Study  Monitor will make arrangements 
for return of study  drug to a designated facility  for destruction .
4.9 Return of Study Drug
It is the Investigator ’s responsibility  to arrange for disposal of all empty  containers, provided that 
procedures for proper disposal have been established according to applicable federal, state, local, 
and institutional guidelines and procedures, and prov ided that appropriate records of disposal are 
kept.
4.10 Retained Samples for Bioavailability  / Bioequivalence
Not applicable.
Clinical Protocol MB102138
BMS -512148 dapagliflozin
Revised Protocol No: 03
Date: 20-Sep- 2017 375 STUDY ASSESSMENTS A ND PROCEDURES
5.1 Flow  Chart/Time and Events Schedule 
Table 5.1-1: Screening Procedural Outline ( MB102138)
ProcedureScreening
Week
-12/ -8aLead -In
Week -4b Notes
Eligibility Assessments
Informed Consent X
Obtain written Assent (If applicable) X
Inclusion/Exclusion Criteria X
Medical History X
Revie w Concomitant Medication X X
ECG X
Safety Assessments
Physical Examination X
Targeted Physical Examination X
Tanner Staging (Investigator determined/ Self-reported ) X See Appendix 3
Vital Signs X X
Height X
Body  Weight X
BMI X
Serious Adverse Events Assessment X X
Adverse Events Assessment X
Clinical Protocol MB102138
BMS -512148 dapagliflozin
Revised Protocol No: 03
Date: 20-Sep- 2017 38Table 5.1-1: Screening Procedural Outline ( MB102138)
ProcedureScreening
Week
-12/ -8aLead -In
Week -4b Notes
Laboratory Tests
Standard Safety Laboratory Panel (Blood /Urine ) X See Appendix 1
GAD/IA2 Autoantibodies X
Fasting Plasma Glucose (FPG) X
HbA1c X
Pregnancy Test (WOCBP only) X For WOCBP only urine test with reflex serum test, if positive.
TSH, (reflex to FT4) X
Hepatitis Screening Panel XIncludes hepatitis s creen panel (anti -HAV [IgM], HbsAg, and 
anti-HCV)
Study Drug / IWRS
Contact IWRS X X
Dispense Study Drug X
General
Provide Dietary and Exercise Counseling X
Provide glucose meter and supplies / instructions X
Provide logs / instructions X
Assessment of signs and symptoms of hypoglycemia 
episodesX
aThe range in duration of the screening period, from Week -12to Week -8, is due to the possibility of considerable delays in the performance and delivery of 
results of GAD/IA2 antibodies testing in some countries. Therefore, if all other screening procedures have been completed dur ing the first 4weeks of screening, 
but a final decision cannot be made due to a delay in results of GAD/IA2 testing, up to 4 additional weeks, i.e, up to a total of 8weeks for all screening procedures, 
will be allow ed until a decision of compliance with inclusion/exclusion criteria is made. 
bLead -in visit can be performed as soon as screening laboratory results have been reviewed, but w ithin 56 days from Screening visit. 
Clinical Protocol MB102138
BMS -512148 dapagliflozin
Revised Protocol No: 03
Date: 20-Sep- 2017 39Table 5.1-2: Short -term Procedural Outline ( MB102138)
ProcedureDay 
1aWk 
2a,bWk 
4aWk 
8aWk
12a,bWk 
16aWk 
20a,bWeek 24 /
ETD(early 
treatm ent 
discontinuation)
/ RescueaNotes
Eligibility Assessments
Inclusion/Exclusion Criteria X
Revie w concom itant medications / 
proceduresX X* X X X* X X* X *Assessed by Phone
Safety Assessments
Physical Examination X
Targeted Physical Examination X X X X
Tanner Staging (Investigator
determined/ Self-reported )X See A ppendix 3
Vital Signs X X X X X
Height X X X X
Body  Weight X X X X
ECG X
Assessment of signs and symptoms 
of hypoglycemia episodesX X* X X X* X X* X *Assessed by Phone
DKA Assessment X X* X X X* X X* X *Assessed by Phone
Serious Adverse Event Assessment X X* X X X* X X* X *Assessed by Phone 
Adverse Events Assessment X X* X X X* X X* X *Assessed by Phone
Laboratory Tests
Standard Safety Laboratory Panel 
(Blood/Urine)X X X X X See Appendix 1
Clinical Protocol MB102138
BMS -512148 dapagliflozin
Revised Protocol No: 03
Date: 20-Sep- 2017 40Table 5.1-2: Short -term Procedural Outline ( MB102138)
ProcedureDay 
1aWk 
2a,bWk 
4aWk 
8aWk
12a,bWk 
16aWk 
20a,bWeek 24 /
ETD(early 
treatm ent 
discontinuation)
/ RescueaNotes
Fasting Lipid panel X XTotal cholesterol, triglycerides, HDL, and 
LDL
Fasting Plasma Glucose (FPG) X X X X
HbA1c X X X X X Results masked
Pregnancy Test (WOCBP only) X* X X X** X X** X*To be performed prior to administration 
of first dose. 
**If appropriate ,parent w ill provide result 
over the phone.
Hom e pregnancy kits will be provided
Spot Urine Glucose X X X X Results masked
Grow th / maturation markers / Bone 
biomarkersX XThyroid -stimulating hormone (TSH), free 
thyroxine, luteinizing hormone (LH), 
follicle -stimulating hormone (FSH), 
estradiol, total testosterone, insulin -like 
grow th factor -1 (IGF- 1), insulin -like 
grow th factor binding protein -3) 
(IGFBP3), calcitonin, 25 -hydroxy 
vitamin D, bone alkaline phosphatase, and 
osteocalcin, parathyroid hormone (PTH).
Blood PK Sampling
PK Panel X X*Samples to be taken pre -dose and 2 hours 
post-dose (± 1 hour)
*Not to be collected at ETD visits
Study Drug / IWRS
Contact IWRS X X X X
Clinical Protocol MB102138
BMS -512148 dapagliflozin
Revised Protocol No: 03
Date: 20-Sep- 2017 41Table 5.1-2: Short -term Procedural Outline ( MB102138)
ProcedureDay 
1aWk 
2a,bWk 
4aWk 
8aWk
12a,bWk 
16aWk 
20a,bWeek 24 /
ETD(early 
treatm ent 
discontinuation)
/ RescueaNotes
Randomize X
Dispense Study Drug X X X X**No drug dispensed during ETD or Rescue 
visit
Rescued subjects will continue w ith their 
current assigned IP regimen .
Study Drug Compliance Review X X X X
General
Provide diet and exercise counseling X X X X X
Dispense Meter Supplies X X X X X
Revie w daily diary of finger -stick 
glucose valuesX X* X X X* X X* X *Assessed by Phone
Provide logs / instructions X X X X X
Assess Rescue X X X* X X* X *Assessed by Phone
aVisits may be scheduled 7 days (of original schedule) to allow  flexibility of scheduling.
bPhone assessments
Clinical Protocol MB102138
BMS -512148 dapagliflozin
Revised P rotocol No: 03
Date: 20-Sep- 2017 42Table 5.1-3: Long -term Procedural Outline ( MB102138)
ProcedureWk 
28a,bWk 
32aWk 
36a,bWk 
40aWk 
46a,bWeek 52 /
ETD / 
RescueaWk 56
Follow
-upNotes
Eligibility Assessments
Revie w concom itant medications / 
proceduresX* X X* X X* X X* *Assessed by Phone
Safety Assessments
Physical Examination X
Targeted Physical Examination X X
Tanner Staging (Investigator 
determined/ Self-reported )X See Appendix 3
Vital Signs X X X
Height X X X
Body  Weight X X X
ECG X
Assessment of signs and 
symptoms of hypoglycemia 
episodesX* X X* X X* X *Assessed by Phone
DKA Assessment X* X X* X X* X *Assessed by Phone
Serious Adverse Event 
AssessmentX* X X* X X* X X* *Assessed by Phone
Adverse Events Assessment X* X X* X X* X X* *Assessed by Phone
Laboratory Tests
Standard Safety Laboratory Panel 
(Blood/Urine)X X X See A ppendix 1
Clinical Protocol MB102138
BMS -512148 dapagliflozin
Revised P rotocol No: 03
Date: 20-Sep- 2017 43Table 5.1-3: Long -term Procedural Outline ( MB102138)
ProcedureWk 
28a,bWk 
32aWk 
36a,bWk 
40aWk 
46a,bWeek 52 /
ETD / 
RescueaWk 56
Follow
-upNotes
Fasting Lipid panel X Total cholesterol, triglycerides, HDL, and LDL
Fasting Plasma Glucose (FPG) X X X
HbA1c X X X
Pregnancy Test (WOCBP only) X* X X* X X* X*If appropriate , parent will provide result over 
the phone.
Hom e pregnancy kits will be provided. 
Grow th/ maturation markers / 
Bone biomarkersXThyroid -stimulating hormone (TSH), free 
thyroxine, luteinizing horm one (LH), 
follicle -stimulating hormone (FSH), estradiol, 
total testosterone, insulin -like grow th factor -1 
(IGF -1), insulin -like growth factor binding 
protein -3) (IGFBP3), calcitonin, 25 -hydroxy 
vitamin D, bone alkaline phosphatase, and 
osteocalcin , parathyroid hormone (PTH).
Study Drug / IWRS
Contact IWRS X X X
Dispense Study Drug X X*No drug dispensed during ETD or Rescue visit
Rescued subjects will continue w ith their current 
assigned IP regimen.
Study Drug Compliance Review  X X X
General
Provide diet and exercise 
counselingX* X X* X X* *Assessed by Phone
Dispense Meter Supplies X X
Revie w daily diary of finger -stick 
glucose valuesX* X X* X X* X *Assessed by Phone
Clinical Protocol MB102138
BMS -512148 dapagliflozin
Revised P rotocol No: 03
Date: 20-Sep- 2017 44Table 5.1-3: Long -term Procedural Outline ( MB102138)
ProcedureWk 
28a,bWk 
32aWk 
36a,bWk 
40aWk 
46a,bWeek 52 /
ETD / 
RescueaWk 56
Follow
-upNotes
Provide logs / instructions X X
Assess Rescue X* X X* X X* X *Assessed by Phone
aVisits may be scheduled 7 days (of original schedule) to allow  flexibility of scheduling.
bPhone assessments
Clinical Protocol MB102138
BMS -512148 dapagliflozin
Revised Protocol No: 03
Date: 20-Sep- 2017 45Table 5.1-4: Early Treatment Discontinuation (ETD) Follow -up -Non-Treatment Phase
ProcedureNon-treatm ent 
Short -term
Follow -up (up to and 
including Wee k24)
Office Visita
,bNon-treatm ent 
Longterm
Follow -up (after 
Wee k 24,up to and 
including Wee k52)
Office 
Visita,bShort -term  and 
Long- term  
Non-treatm ent 
Follow -up
Phone Assessmentb,cNotes
Safety Assessments
Targeted physical examination X X
Vital signs X X
Body  weight and height X X
Revie w concom itant medications X X X
AE assessment X X X 
Standard safety laboratory panel 
(Blood /Urine )X X Appendix 1
HbA1c X X
aIn-office assessments to occur at time points corresponding to originally scheduled Short -term (up to and including Week 24) and Long -term (after 
Week 24,up to and including Week 52) visits
bVisits may be scheduled 7 days (of original schedule) to allow  flexibility of scheduling
cPhone assessments only to occur at time points correspo nding to originally scheduled that is not identified above as an in office visit
Clinical Protocol MB102138
BMS -512148 dapagliflozin
Revised Protocol No: 03
Date: 20-Sep- 2017 465.1.1 Retesting During Screening or Lead- in Period
The laboratory  parameters listed below may be repeated once in an effort to find all possible 
well-qualified subjects. Consultation with the Medical Monitor may be needed to identify  whether 
repeat testing of any  particular parameter is clinically  relevant.
Retesting of screening laboratory  tests will only be allowed under the following circumstances, 
and must be performed within 10 day s from the original screening visit:
Repeat HbA1c testing if results fall 0.3% from inclusion range
Repeat FPG testing if results fall + 9 mg/dL (0.5 mmol/ L) from inclusion range
Any new result will override the previous result (i.e., the most current result prior to 
Randomization) and is the value by which study inclusion will be assessed, as it represents the 
subject’s most current, clinical state.
Other individual laboratory  screening tests for which the results are in error, borderline, or 
indeterminate for inclusion in the study  may be repeated once for confirmation during the 
Screening period if they are within 25% of the exclusion limit. Upon retesting, subjects whose 
results remain outside this threshold should not be randomized.
5.2 Study Materials
The Sponsor or designee will supply  the sites with the following materials:
Blood glucose and ketone meters. One (1) meter will be provided to each study  subject at 
enrollment and one (1) meter will be provided to each investigative site.
Glucose and ketone test strips
Lancets
Glucose control solutions
Subject education and site support materials
Electronic case report forms (eCRFs) [Serious Adverse Event (SAE) Forms, Pregnancy  
Surveillance Forms]
Subject Alert Cards
Study  Drug inventory  control forms
Subject Diary :
oFull diary  review b y site staff is required for this study
oUse of subject diaries is mandatory  for the study and will be maintained by each study  
subject for documentation of SMBG results, ketone results, study  medication dosing, 
hypoglycemia episodes (if applicable), symptoms potentially  associated with DKA and 
relevant risk factors, WOCBP urine pregnancy  test results (if applicable).
-eCRF pages will be provided to the sites 
so they can record the relevant data 
obtained from the diaries into the study  database. 
-Subjects are to record any hypoglycemic symptoms and symptoms potentially  
associated with DKA they may experience and SMBG and ketone values if they 
Clinical Protocol MB102138
BMS -512148 dapagliflozin
Revised Protocol No: 03
Date: 20-Sep- 2017 47conducted the test when they have symptoms in their diaries. All events recorded 
in subject diary  are to be reviewed b y site staff according to Section 5.3.1
Any other materials as locally  required or agreed.
The central laboratory  will provide all laboratory -related materials including home pregnancy 
testing kits for WOCBP to the st udy sites.
5.3 Safety  Assessments
Safety  assessments will include AEreporting as well as marked abnormalities in clinical laboratory  
tests. Please refer to Appendix 1 for details on central laboratory  assessments.
The procedures described in the sections thatfollow will also be completed to ensure subject’s 
safet y.
It is the Investigator 's responsibility  to report, as applicable based on the Investigator 's judgment 
and the subject's medical history , related AEs as defined in Section 6. Additional information, 
including but 
not limited to completion of supplemental eCRFs or questionnaires may be requested 
for certain AEs and/or laboratory  abnormalities which are reported/identified during the course of 
the study .
5.3.1 Self-Monitored Blood Glucose (SMBG), Self-Monitored blood Ketones 
and Guidance on Management and Reporting of Hypoglycemia 
Episodes
5.3.1.1 Self-Monitoring of Blood Glucose (SMBG)
Glucose meters will be supplied to each study  site. At the entry  into Lead-In (Week -4 visit), 
subjects will receive a glucose meter, supplies and instruction on their use. Supplies will be 
provided to allow for approximately  60 blood glucose assessments per month for the duration of 
the study . Subjects should be encouraged to measure and record fasting blood glucose levels at 
least once per day. The Investigator may require more frequent readings based on local clinical 
practice. Subjects should bring their glucose meter with them to each study  visit to ensure that it 
is functioning properl y. Subjects may keep the glucose meters at the end of the study , but the 
Sponsor will not continue to provide glucose meter supplies once the study is complete.
In the occurrence ofhypoglycemic symptoms or in the event of an unusually  high or low blood 
glucose value, subjects should contact the I nvestigator. In addition, study  subjects should compl y 
with site’s instructions with regard to self-monitoring of blood glucose and should report to the 
site blood glucose values and/or signs and sy mptoms suggestive of a hy pogly cemia episode. 
The memory  of the glucose meter should be reviewed to compare with the subject’s hypoglycemia 
episode log, as applicable. The glucose values should be reviewed by the site to identify  any 
unusual high or low values, and to confirm that the values (from the glucose meter’s memory 
and/or from the subject’s hy poglycemia log) were obtained for the subject. If finger- stick glucose 
values are discordant from glycemic control assessed by the central laboratory  or with clinical 
symptoms, the subject’s glucose meter should be tested and the procedure for using it reviewed 
with the subject .
Clinical Protocol MB102138
BMS -512148 dapagliflozin
Revised Protocol No: 03
Date: 20-Sep- 2017 485.3.1.2 Self-Monitored Blood Ketone Testing and Guidance on Management 
and Reportin g of Diabetic Ketoacidosis Episodes
Diabetic ketoacidosis has been identified as a potential risk in subjects with diabetes receiving 
SGL T-2 inhibitors. Subjects and their family  members must be aware of the possibility  that DKA 
may occur, the signs and sy mptoms and the dangers associated with DKA. Subjects will receive a 
combined glucose and ketone meter and sufficient supplies for testing at the entry  into Lead-In 
(Week -4 visit). Subjects will also be trained in the procedure of conducting blood ketone t esting 
according to the manufacture r’s specifications. 
Subjects will be instructed to measure their blood ketones using the glucose and ketone meter 
provided b y the Sponsor at least at the following frequency :
Between Randomization (Day  1 visit) and Week 4 visit: once a day
Between Week 4 visit and Week 24 visit: at least once every  2 weeks
Between Start of open -label extension period (Week 24 visit) and Week 28 visit: once a day
Between Week 28 visit and Week 52 visit: at least once every  2 weeks
When exp eriencing potential sy mptoms/signs of DKA, including but not limited to; excessive 
thirst, nausea and vomiting, frequent urination, weakness or fatigue, fever, fruity -scented 
breath, confusion, and/or consistently  elevated blood glucose: at least once a day
During an acute illness: at least once a day
Blood ketone test results, symptoms potentially  associated with DKA and relevant risk factors 
(e.g.,missed insulin injection, infection, etc) should be recorded in the subject diary . As DKA may 
present differently  and occur at lower glucose values than expected, particular attention should be 
paid to episodes of nausea and vomiting as indicative DKA symptoms, particularl y in subje cts 
requiring insulin therapy . Subjects should contact the site for assista nce with diabetes management 
in the event that they  develop such sy mptoms or when the blood ketone reading is 0.6 mmol/ Lor 
above, even if their blood glucose levels are not elevated at that time. 
The action, follow -up and monitoring plan will be at the discretion of the Investigator and will 
depend on their judgment of severity  based on signs/sy mptoms of DKA, risk factors, relevant 
contributing factors, and blood glucose (with the caveat that the blood glucose may  be lower than 
would be otherwise expected given elevated ketone levels). 
The blood ketone values should be recorded and will be reviewed by the site to identify  any 
unusual high values, and to confirm that the values (from the glucose and ketone meter’s memory 
and/or from the subject’s diary ) were obtained from the subject. If finger -stick blood values are 
discordant from glycemic control assessed by the central laboratory  or with clinical symptoms, the 
subject’s glucose and ketone meter should be tested and the procedure for using it reviewed wi th 
the subject. Investigators will examine if any of the elevated ketone values from the 
subject’s diary 
are associated with a DKA event. If yes, investigators will document all DKA related sy mptoms, 
relevant risk factors, and available laboratory  test results (including blood ketone values and blood 
glucose values measured by the glucose/ketone meter) on the DKA eCRF pages and report this 
event to the Sponsor. Signs and sy mptoms associated with DKA events should not be reported on 
Clinical Protocol MB102138
BMS -512148 dapagliflozin
Revised Protocol No: 03
Date: 20-Sep- 2017 49the AE eCRF page, unless the event fulfills protocol criteria for anSAE (see Section 6.1.1), in 
which case an SAE form must be completed in addition to the DK A eCRF pages.
5.3.1.3 Guidance on Management and Reporting of Hypoglycemia Episodes
Hypoglycemia may be an expected event in subjects who are treated for diabetes. Subjects and 
their family  members must be aware of the possibility  that hypoglycemia may occur andofthe 
dangers associated with low blood sugar. Study  subjects must be properly  instructed on the 
recognition and management of hypogly cemia. Subjects should record in their log books any 
hypoglycemic symptoms. They  should be encouraged to 
measure, when possible, their blood 
glucose values when they have symptoms of hypogly cemia. Subjects should carry with them easily 
ingestible forms of carbohy drate at all times in order to treat an event of hypogl ycemia should it 
occur.
During clinical trials, subjects frequently  report symptoms of hypoglycemia when asked, even 
when treated with placebo or medications not otherwise associated with hypoglycemia. As 
hypoglycemia is an important event associated with diabetes therap y, all episodes which could be 
consistent with the clinical definition of hypoglycemia as assessed by the Investigator should be 
documented and reported on the appropriate eCRF page.
The Investigator is responsible for questioning the subject about all symptoms reported on the 
hypoglycemia log and for determining if they meet the clinical definition of hy pogly cemia. Only 
symptoms and/or blood glucose values deemed by the Investigator to meet the definition of 
hypoglycemia should be reported on the hypogly cemia eCRF pages. Signs and symptoms of 
hypogly cemia, hypoglycemia episode or discontinuation due to hypoglycemia should not be 
reported on the AE eCRF page, unless the event fulfills protocol criteria for an SAE (see Section 
6.1.1), in which case an SAE form must be completed in addition to the hypoglycemia eCRF pages 
for h ypoglycemia.
Hypoglycemia episodes will be classified in the clinical study  report (CSR) according to the 
International Societ y for Pediatric and Adolescent Diabetes (ISPAD) criteria20and the ADA 
criteria .21
5.3.2 Guidance on Assessment of Urina ry Tract Infections & Hematuria
5.3.2.1 Guidance on Assessment of Urinary Tract Infections
The following is presented to assist in the classification and management of urinary  tract infections
(UTIs) . It is not intended to supplant investigators’ clinical judgment:
Study drug should be withheld in subjects with clinical evidence of upper tract UTI 
(e.g.,pyelonephritis) or presumed urosepsis until the course of treatment of the infection has 
been completed and clinical recovery has occurred.
It is recommended that a follow -up urine culture be obtained within 7 days of clinical 
recovery from all urinary tract infections. Whether or not additional therapy is prescribed 
becaus e of culture results should be determined by Investigator judgment, after consultation 
with the Medical Monitor.
Clinical Protocol MB102138
BMS -512148 dapagliflozin
Revised Protocol No: 03
Date: 20-Sep- 2017 50It is the Investigator 's responsibility to report, as applicable based on Investigator's 
judgment and subject's medical history, related AEs as defined in Section 6.
Additional information, including but not limited to completion of supplemental eCRFs or 
questionnaires may be requested for certain AEs and/or laboratory abnormalities which are 
reported/identified during the course of the study.
Asymptomatic bacteriuria 
During enrollment, treatment, and follow -up of patients in this trial, the Investigator may discover 
a patient with asymptomatic bacteriuria. Asymptomatic bacteriuria is defined as the presence of 
105colony  forming units/mL of bacteria, in a properly collected voided urine specimen, without 
signs or symptoms typically  attributed to UTI. In this study , the central laboratory  will report 
urinary  dipstick test results for hemoglobin but will not routinely  report the results of urinary 
dipstick tests for leukocy te esterase as a screening test for pyuria in surveillance urine 
examinations.
5.3.2.2 Guidance on Assessment o f Hematuria
All events of hematuria (microscopic and/or macroscopic) during the study should be worked up 
for a possible cause as per local guidelines.
5.3.3 Guidance on Assessment of Hepatic Laboratory Abnormalities
An independent Hepatic Adjudication Committee, blinded to the treatment of the subjects, will 
determine the probability  that drug-induced liver injury  (DILI) is the cause of liver-related 
abnormalities, including , but not limited to:
Hepatic events related or leading to death ( occurring with in 30 day s before death)
Liver la boratory  abnormalities such as:
oelevated AST and/or ALT 3x ULN and TB2x ULN (within 14 days of the AST 
and/or ALT elevation) 
oAST and/or ALT 10x ULN
A separate Adjudication Charter will define and describe the procedure for the handling, reporting ,
and classification of these cases .
The following is presented to assist in the evaluation and management of hepatic laboratory  values. 
It is not intended to supplant Investigator’s clinical judgment. Subjects who expe rience ALT 
and/or AST values > 3X ULN confirmed with a repeated test will have the following performed 
within 3 day s of the confirmed laboratory  results:
Adverse event assessment
Physical examination for jaundice and other signs of liver diseases
Review of relevant risk factors and current history  focusing on possible causes of the increased 
ALT and/or AST and/or TB, including:
oUse of suspect concomitant medication (including over -the-counter 
[i.e.,acetaminophen/paracetamol ], herbal and vitamin preparation s)
Clinical Protocol MB102138
BMS -512148 dapagliflozin
Revised Protocol No: 03
Date: 20-Sep- 2017 51oRecent alcohol consumption or recreational drug/narcotic use
oRecent unaccustomed phy sical exertion
oOccupational or environmental exposure to hepatotoxins
oOther conditions which may  cause liver diseases or which may  cause abnormal test 
results
oSpecialize d Liver Laboratory  Panel (see Appendix 1)
Additional information, including but 
not limited to completion of supplemental eCRFs or 
questionnaires, may be requested for certain AEs and/or laboratory  abnormalities which are 
reported /identified as part of th e hepatic safet y surveillance.
For subjects who are discontinued from study  medication as a result of sustained elevated liver 
safet y abnormalities, as described in Section 3.5, additional blood sampling must be done within 
3days of the confirmed laboratory  results (see Appendix 2), in conjunction with an Early 
Treatment Discontinuation (ETD) visit, in addition to the procedures noted above. A referral 
consultation to a hepatologist or gastroenterologist (specializing in liver abnormalities) should be 
obtained. Any additional tests and/or examinations should be carried out at the discretion of 
the Investigator. Any further investigations and laboratory 
results for subjects with 
abnormal laboratory values at the follow -up visit should be made available to the Sponsor 
upon request .
5.3.4 Physical Examination
A targeted physical examination should include cardiovascular, lungs, abdomen, and 
extremities, and any  organ sy stems pertinent to the subject’s signs, s ymptoms, or AEs
A full phy sical examination should include general appearance, head, ey es, ears, nose, throat, 
neck, cardiovascular, lungs, abdomen, lymph nodes, extremities, neurolog ical, skin, and 
musculoskeletal
The individual performing the physical examinations must be licensed by state law (or 
applicable local law) to perform this procedure.
5.3.5 Blood Pressure and Heart Rate
Blood pressure andHR measurements must be taken consistently  throughout the study . Only  use 
either the right or the left arm when measuring these parameters. Document which a rm was used 
along with the observer’s initials; the same arm and position should be used at each visit. The 
subject should be allowed at least 5 minutes of rest before measurement. Blood pressure should be 
measured with the subject’s arm resting on a table, and with the subject’s back support edand feet 
flat on the floor.
Blood pressure and HR will be determined from three replicate measurements obtained at least 
1minute apart. The average BP and HR will be determined from these 3 replicate measurements 
and reported in the eCRF.
All measurements should occur at least 8 hours after the last ingestion of caffeine, alcohol, or 
nicotine.
Clinical Protocol MB102138
BMS -512148 dapagliflozin
Revised Protocol No: 03
Date: 20-Sep- 2017 52It is critical that the BPand HRmeasurements are obtained prior to the administration of blinded 
study  medication .
5.3.6 Guidance on Volume Depletion
Dapagliflozin has a modest diuretic effect. The risk of volume depletion is enhanced when two 
diuretics are used in combination and in patients that otherwise are at risk for volume depletion. 
Therefore, caution should be exercised when administering to patients at risk for volume depletion 
due to co-existing conditions or concomitant medications, such as loop diuretics. These patients 
should be carefully  monitored for volume status, electroly tes, and renal function.
5.3.7 Supplemental Visits
5.3.7.1 Rescue or Early Treatment Discontinuation Visit 
Any subject who qualifies for rescue or discontinues during the study  periods must have all 
Rescue /ETD visit procedures performed at the time of s tudy discontinuation or rescue. The IWRS
must be called to record the subject status (i.e., rescue, or discontinuation status). All subjects who 
are rescued or who discontinue study  drug should remain in the study  and follow the visit schedule.
For subject s qualify ing for rescue: Rescue procedures will be performed and the subject will 
then continue in the treatment period according to the regular visit schedule. The Rescue/ETD 
supplemental eCRF will need to be completed to collect Rescue -related endpoint d ata.
Subjects who discontinue study  medication should have all ETD procedures performed 
(Rescue/ETD visit) and recorded in the Rescue/ETD supplemental eCRF . Subjects will then 
continue in the study  and undergo non-treatment follow - up visit assessments according to their 
original visit schedule (Table 5.1 -4).
5.3.7.2 Other Supplemental (Unscheduled) Visits
At any time during the trial, the I nvestigator may at his/her discretion arrange for a subject to have 
an unscheduled (supplemental) assessment(s), especially  in the case of AEs that require follow -up. 
If a subject is seen for an unscheduled assessment, the appropriate Supplemental Pages of the 
eCRF must be completed.
5.3.8 Imaging Assessment for the Study
Not applicable .
5.4
Efficacy  Assessments
Assessments consist of the central laboratory  measurement of the HbA1c, and other relevant 
laboratory  tests collected during the study .
5.5 Pharmacok inetic A ssessments
Blood samples for determinatio n of the level of dapagliflozin in plasma will be taken at the times 
presented in Table 5.5-1 . Samples will be collected, labeled, stored and shipped asdetailed in 
Laboratory  Manual.
Samples for determination of drug concentration in plasma will be analy zed by appointed 
laboratory  on behalf of the Sponsor or designee using appropriate bioanaly tical methods. Full 
Clinical Protocol MB102138
BMS -512148 dapagliflozin
Revised Protocol No: 03
Date: 20-Sep- 2017 53details of the analytical methods used will be described in a separate bioanal ytical report. Only  
samples from patients on relevant active study  drug will be analyzed. Samples from patients not 
dosed with the relevant active study  treatment will only be analyzed on a ‘for cause’ basis, for 
example, if there is a suspicion that a patient has been dosed incorrectly .
Pharmacokinetic samples will be disposed of after the Bioanal ytical Report finalization or 
6months after issuance of the draft Bioanal ytical Report (whichever is earlier), unless requested 
for future analyses. All samples still within the known stability  of the analy ses of interest at the 
time of receipt by  the bioanal ytical laboratory  will be anal yzed. Pharmacokinetic samples may  be 
disposed of 
or destroy ed and anony mized by pooling. Additional analy ses may be conducted on 
the anon ymized, pooled PK samples to further evaluate and validate the analy tical method. Any 
results from such analy ses may  be reported separately  from the CSR.
Incurred sample reproducibility  analysis, if any, will be performed alongside the bioanaly sis of the 
test samples. The results from the evaluation will not be reported in the CSR but separately in a 
Bioanal ytical Report.
Table 5.5-1: Sampling Schedule
Study DayTime 
(Relative to 
Dosing)
HourTime 
(Relative to Dosing)
Hour: MinPK
Blood Sam ple
Week 16 0 (predose) 2 hours post -dose ( 1 hour) X
Week 24 0 (predose) 2 hours post-dose ( 1 hour) X
Rescue visita0 (predose) 2 hours post -dose ( 1 hour) X
aIf applicable during the short -term treatment period only.
5.6 Biomarker Assessments
Not applicable
5.7 Outcomes Research A ssessments
Not applicable
5.8 Other Assessments 
5.8.1 Diet and Exercise Counseling 
Starting at entr y into Lead -In (Week -4), subjects will be instructed on a diet and exercise program 
in accordance with the ADA or similar local guidelines to be followed for the study  duration.
A Registered Diet itian, Registered Nurse, Phy sician, Certified Diabetes Educator, Nutritionist, or 
other qualified member of the study  team who has appropriate documented training, will provide 
this counseling.
Clinical Protocol MB102138
BMS -512148 dapagliflozin
Revised Protocol No: 03
Date: 20-Sep- 2017 545.8.2 Weight and Height
Body weight and height will be measured according to the schedule presented in the study  flow 
chart/time and event schedule (see Section 5.1) and will be recorded in the eCRF. 
The study -site staff should use a digital precision scale if possible, and record the weight to the 
first decimal point (e.g., 69.3 kg). The subject should wear a standard hospital -type gown or 
equivalent light indoor clothing, 
shoes removed, and bladder empt y for the body  weight 
measurement at each visit. Subjects should be weighed on the same scale at all visits.
Measurement of height should be performed with the subject’s shoes removed. The subject’s knees 
should be s traightened, head held erect and ey es forward.
Method of B ody Mass Index (B MI)calculation :
Use actual height and weight
To calculate BMI:
oConvert pounds (lbs) to kilograms (kg = lb / 2.2)
oConvert inches (in) to centimeters (cm = in X 2.54)
oBMI = (wei ght in kg) / (height in cm/100)2
oRound to one decimal place (if 0.05 or greater, round up)
5.9 Results of Central A ssessments 
Blood and urine samples will be obtained at specified time points for laboratory  evaluations 
(seeAppendix 1). The central laboratory  for this study  will perform the analy sis of all scheduled 
laboratory  tests and will provide reference ranges for these tests. The central laboratory  will 
provide specific instructions for collection, processing, packaging, and shipping of all samples.
For the duration of the double -blind treatment period (Day  1 to Week 24), the HbA1c and the 
urinary  glucose values, including the urinary  glucose:creatinine ratio, will be masked to the 
Sponsor and will not be available to the Investigator. During the open -label long- term extension 
period (after the Week 24visit to Week 52), the above measurements will be unmasked and 
available to the Sponsor and the Investigator.
6 ADVERSE EVEN TS
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a 
pre-existing medical condition in a clinical investigation subject administered study  drug and that 
does not necessarily  have a causal relationship with this treatment. An AE can therefor e be any 
unfavorable and unintended sign (such as an abnormal laboratory  finding), symptom, or disease 
temporally  associated with the use of study  drug, whether 
or not considered related to the study 
drug.
Clinical Protocol MB102138
BMS -512148 dapagliflozin
Revised Protocol No: 03
Date: 20-Sep- 2017 55The causal relationship to study drug is determine d by a ph ysician and should be used to assess all 
AEs. The causal relationship can be one of the following:
Related: There is a reasonable causal relationship between study drug administration and 
the AE
Not related: There is not a reasonable causal relationship between study drug 
administration and the AE
The term "reasonable causal relationship" means there is evidence to suggest a causal relationship. 
Adverse events can be spontaneously  reported or elicited during open -ended questioning, 
examinati on, or evaluation of a subject. (In order to prevent reporting bias, subjects should not be 
questioned regarding the specific occurrence of 1 or more AEs.)
The Sponsor or designee will be reporting AEs to regulatory  authorities and ethics committees 
accord ing to local applicable laws including European Directive 2001/20/EC and Food and Drug 
Administration (FDA )Code of Federal Regulations 21 CFR Parts 312 and 320 .
6.1 Serious A dverse Events
A Serious Adverse Event (SAE) is any  untoward medical occurrence that at an y dose: 
results in death
is life -threatening (defined as an event in which the subject was at risk of death at the time of 
the event; it does not refer to an event which hypothetically might have caused death if it were 
more severe)
requires inpatient hospitalization or causes prolongation of existing hospitalization (see NOTE
below)
results in persistent or significant disability /incapacity
is a congenital anomal y/birth defect 
is an important medical event (defined as a medical event(s) that may not be immediatel y 
life-threatening or result in death or hospitalization but, based upon appropriate medical and 
scientific judgment, may jeopardize the subject or may require intervention [e.g., medical, 
surgical] toprevent one of the other serious outcomes listed in the definition above.) Examples 
of such events include, but are not limited to, intensive treatment in an emergency  room or at 
home for allergic bronchospasm; blood dyscrasias or convulsions that do not result in 
hospitalization.) Potential DILI is also considered an important medical event. (See Section 6.6
for the definition of poten tial DILI.)
Suspected transmission of an infectious agent (e.g., pathogenic or nonpathogenic) via the study 
drug is an SAE.
Although pregnancy , overdose, cancer, and potential DILI are not always serious by regulatory 
definition, these events must be hand led as SAEs. (See Section 6.1.1 for reporting pregnancies).
Any component of a study  endpoint that is consider ed related to study  therap y (e.g.,death is an 
endpoint, if death occurred due to anaphy laxis, anaphy laxis must b e reported) should be reported 
as an SAE (see Section 6.1.1 for reporting details ).
Clinical Protocol MB102138
BMS -512148 dapagliflozin
Revised Protocol No: 03
Date: 20-Sep- 2017 56NOTE : 
The following hospitalizations are not consi dered SAEs in the Sponsor’s clinical studies: 
a visit to the emergency  room or other hospital department < 24 hours, that does not result in 
admission (unless considered an important medical or life -threatening event)
elective surgery , planned prior to signing consent
admissions as per protocol for a planned medical/surgical procedure
routine health assessment requiring admission for baseline/trending of health status 
(e.g.,routine colonoscopy )
medical/surgical admission other than to remed y ill health and planned prior to entry  into the 
study . Appropriate documentation is required in these cases .
admission encountered for another life circumstance that carries no bearing on health status 
and requires no medical/surgical interventio n (e.g., lack of housing, economic inadequacy , 
caregiver respite, famil y circumstances, administrative reason ).
admission for administration of anticancer therapy  in the absence of any other SAEs (applies 
to oncology  protocols)
6.1.1 Serious Adverse Event Collec tion and Reporting
Sections 5.6.1 and 5.6.2 in the IB represent the Reference Safety  Information to determine 
expectedness of SAEs for expedited reporting. Following the subject’s written consent to 
participate in the study , all SAEs, whether related or not related to study  drug, must be collected, 
including those thought to be associated with protocol -specified procedures. All SAEs must be 
collected that occur during the screening period and within 28 days of discontinuation of dosing. 
If applicable, SAEs must be collected that relate to any  later protocol -specified procedure ( e.g., a 
follow -up skin biopsy ). 
The Investigator must report any SAE that occurs after these time periods and that is believed to 
be related to stud y drug or protocol -specified proce dure. 
An SAE report must be completed for an y event where doubt exists regarding its seriousness. 
If the Investigator believes that an SAE is not related to study  drug, but is potentially  related to the 
conditions of the study  (such as withdrawal of previous therapy  or a complication of a study 
procedure), the relationship must be specified in the narrative section of the SAE Report Form.
SAEs, whether related or not related to study  drug, and pregnancies must be reported to the 
Sponsor within 24 hours of awareness of the event. 
All SAEs will be recorded in the CRF. If any SAE occurs in the course of the study , then 
investigators or other site personnel must inform the appropriate AstraZeneca representatives 
within 1 day  i.e., immediately  but no later than 24 hours of when he or she becomes aware of it.
The designated AstraZeneca representative will work with the Investigator to ensure that all the 
necessary  information is provided to the AstraZeneca Patient Safety  data site within 1calendar 
day of initial receipt for fatal and life-threatening events and within 5 calendar days of initial 
receipt for all other SAEs.
Clinical Protocol MB102138
BMS -512148 dapagliflozin
Revised Protocol No: 03
Date: 20-Sep- 2017 57For fatal or life-threatening AEs where important or relevant information is missing, active 
follow -up must be undertaken immediat ely. Investigators or other site personnel must inform 
AstraZeneca representatives of any follow -up information on a previously  reported SAE within 
1 calendar day, i.e., immediatel y but no later than 24 hours of when he or she becomes aware of 
it.
Serious adverse events must be recorded on the SAE Report Form; pregnancies on a Pregnancy 
Surveillance Form (electronic or paper forms). The preferred method for SAE data reporting 
collection is through the eCRF. The paper SAE/pregnancy surveillance forms are onl y intended as 
a back -up option when the eCRF s ystem is not functioning. In this case, the paper forms are to be 
transmitted via email or confirmed facsimile (fax) transmission to:
SAE Email Address: 
USA
SAE Telephone Number: 
SAE Facsimile Number: 
Europe
SAE Telephone Number:
SAE Facsimile Number: 
For studies capturing SAEs through electronic data capture, electronic submission is the required 
method for reporting. In the event the electronic system is unavailable for transmission, paper 
forms must be used and submitted immediately . When paper forms are used, the original paper 
forms are to remain on site.
If only  limited information is initially  available, follow -up reports are required. (Note: Follow -up 
SAE reports must include the same investigator term(s) initially  reported.) 
If an ongoing SAE changes in its intensity  or relationship to study  drug or ifnew information 
becomes available, the SAE report must be updated and submitted within 24 hours to the Sponsor 
using the same procedure used for transmitting the initial SAE report.
All SAEs must be followed to resolution or stabilization .
6.2 Nonserious A dverse Events
Anonserious adverse event is an AE not classified as serious.
Intensit y will be graded according to the following definitions:
mild (awareness of sign or sy mptom, but easil y tolerated)
moderate (discomfort sufficient to cause interference with normal activities)
severe (incapacitating, with inability  to perform normal activities)

Clinical Protocol MB102138
BMS -512148 dapagliflozin
Revised Protocol No: 03
Date: 20-Sep- 2017 58It is important to distinguish between serious and severe AEs. Severit y is a measure of intensity 
whereas seriousness is defined by the criteria in Section 6.1. An AE of severe intensity  need not 
necessarily  be considered serious. For example, nausea that persists for several hours may be 
considered se vere nausea, but not a SAE unless it meets the criteria shown in Section 6.1. On the 
other hand, a stroke that results in only a limit
ed degree of disability  may be considered a mild 
stroke but would be a SAE when it satisfies the criteria shown in Section 6.1.
6.2.1 Nonserious Adverse Event Collection and Reporting
Thecollection of nonserious AE information should begin at initiation of study  drug. Nonserious 
AE information should also be collected from the start of a placebo lead-in period or other 
observational period intended to establish a baseline status for the s ubjects. 
Nonserious AEs should be followed to resolution or stabilization, or reported as SAEs if they 
become serious (see Section 6.1.1). Follow - up is also required for nonserious AEs that cause 
interruption or discontinuation of study drug and for those present at the end of study treatment as 
appropriate. All identified nonserious AEs must be recorded and described on the nonserious A E 
page of the CRF (paper or electronic). 
Completion of supplemental CRFs may  be requested for AEs and/or laboratory abnormalities that 
are reported/identified during the course of the study.
6.3 Laboratory  Test Result Abnormalities
The following laboratory test result abnormalities should be captured on the nonserious AE CRF 
page or SAE Report Form (paper or electronic) as appropriate:
Any laboratory  test result that is clinically  significant or meets the definition of an SAE 
Any laboratory test result abnorm ality that required the subject to have study  drug discontinued 
or interrupted
Any laboratory test result abnormality  that required the subject to receive specific corrective 
therap y.
It is expected that wherever possible, the clinical rather than laboratory  term would be used by  the 
reporting investigator ( e.g., anemia versus low hemoglobin value).
6.4 Pregnancy
If,following initiation of the study  drug, it is subsequently  discovered that a study  subject is 
pregnant or may have been pregnant at the time of study exposure, including during at least 
5half-lives after product administration, the Investigator must immediately  notify  the Medical 
Monitor or appropriate AstraZeneca representatives of this event and complete and forward a 
Pregnancy  Surveillance Form to AstraZeneca or designee within 24 hours of awareness of the 
event and in accordance with SAE reporting procedures described in Section 6.1.1.
If pregnant the study  drug shall be immediatel y discontinued.
Follow -
up information regarding the course of the pregnancy , including perinatal and neonatal 
outcome and, where applicable, offspring information must be reported on the Pregnancy 
Surveillance Form.
Clinical Protocol MB102138
BMS -512148 dapagliflozin
Revised Protocol No: 03
Date: 20-Sep- 2017 596.5 Overdose
An overdose is defined as the accidental or intentional administration of any dose of a product that 
is considered both excessive and medically  important. All occurrences of overdose must be 
reported as an SAE (see Section
6.1.1 for reporting details.).
6.6 Potential Drug Induced Liver Injur y (DILI)
Wherever possible, timely  confirmation of initial liver-related laboratory abnormalities should 
occur prior to the reporting of a potential DILI event. All occurrences of potential DILIs, meeting 
the defined criteria, must be reported as SAEs (see Section 6.1.1 for reporting details).
Potential DILIis defined as: 
1.Aminotransferases ( AT) (ALT or AST) elevation > 3 times ULN
AND
2.Total bilirubin (TB) > 2 times ULN, without initial findings of cholestasis (elevated serum 
alkaline phosphatase),
AND
3.No other immediatel y apparent possible causes of AT elevation and hyperbilirubinemia, 
including, but not limited to, viral hepatitis, pre -existing chronic or acute liver disease, or the 
administration of other drug(s) known to be hepatotoxic.
6.7 Other Safety  Considerations
Any significant worsening noted during interim or final physical examinations, ECG , x-ray 
filming ,any other potential safet y assessment required or not required by  protocol should also be 
recorded as a nonserious or serious AE, as appropriate, and reported accordingl y. 
7 DATA MONITORING COMM ITTEE A ND OTHER COMM ITTEES
7.1 Data Monitoring Committees
An independent Data Monitoring Committee (DMC) comprised of pediatric and endocrine 
therapeutic area specialists and statisticians will be formed and will convene on a regular basis to 
review trial data. The DMC will be responsible for safeguarding the interests of the subjects in the 
trial byassessing the safety  and efficac y of th e interventions during the trial, and for reviewing the 
overall conduct of the clinical trial. The DMC will provide recommendations about stopping or 
continuing the trial and will be governed b y a separate DMC Charte r.
7.2 Hepatic A djudication Committee
An independent Hepatic Adjudication Committee, blinded to the treatment of the subjects, will 
determine the probability that DILI is the cause of liver-related abnormalities, including but not 
limited to, hepatic disorders leading to death, and liver laboratory  abnormalities such as elevated 
AST and/or ALT with or without TB elevations (see Section 5.3.3 for more details). 
A separate Adjudication Charter will define and describe the procedure for the handling, reporting 
and classification of these events.
Clinical Protocol MB102138
BMS -512148 dapagliflozin
Revised Protocol No: 03
Date: 20-Sep- 2017 607.3 Diabetic Ketoacidosis (DKA ) Adjudication Committee
An independent DKA Adjudication Committee, blinded to the treatment of the subjects, will 
adjudicate all potential events of DKA. 
A separate Adjudication Charter will define and describe the procedure for the handling, reporting 
and classification of thes e events .
8 STATISTICA L CONSIDERA TIONS
8.1 Sample Size Determination
In order to inform the design of this study , a Bayesian approach was employ ed to predict the 
potential efficacy  of dapagliflozin on HbA1c in pediatric patients from the existing data and 
knowle dge in adult T2DM patients.
Simulation results suggest a difference versus placebo in HbA1c of -0.78% for dapagliflozin 
10mg. Based on this estimated treatment difference of 0.78% and assuming a standard deviation 
of 0.9% for change from baseline in HbA1c at Week 24, a sample size of 25per treatment group 
has 85% power to demonstrate the superiority  of dapagliflozin 10mg to placebo (where superiorit y 
is defined as a placebo -corrected HbA1c at 24 weeks indicating greater improvement that is 
statistically  significant) at a two -sided alpha level of 5 percent. To ensure that at least 50 subjects 
will complete the 24-week treatment period on IP and the Week 24 assessment, at least 66 subjects 
will be randomized .
8.2 Populations for A nalyses
The Enrolled Subjects D ata Set will consist of all subjects who sign informed consent.
The Randomized Subjects Data Set will consist of all randomized subjects who receive 
at least 
one dose of study  medication during the treatment period. This is also known as the Intent to 
Treat population. This will be the primary  efficacy  data set. Data in this data set will be 
analyzed based on randomized treatment group.
The Evaluable Subjects Data Set will be a subset of the Randomized Subjects, with all data 
points collected after relevant protocol deviations are excluded from the data set. Relevant 
protocol deviations are defined as deviations that could potentially  affect the interpretabilit y of 
the study  results. This is also known as the per -protocol population. This data set will be us ed 
for sensitivity  analy ses of the primary  efficacy  endpoint if > 10% of subjects in any  treatment 
group have relevant protocol deviations.
The Treated Subjects Data Set will consist of all subjects who receive at least one dose of study  
medication during the treatment group. This will be the primary  safety data set. Data in this 
data set will be analy zed based on randomized treatment, except in cases where a subject 
received a different treatment for the entire course of his/her participation in the treatm ent 
period. I n this case, safety  data for such a subject will be analy zed based on the first treatment 
the subject actuall y received.
Pharmacokinetic Anal ysis Data Set will include all patients who received a dapagliflozin dose 
and have collected at least 1 PK sample .
Clinical Protocol MB102138
BMS -512148 dapagliflozin
Revised Protocol No: 03
Date: 20-Sep- 2017 618.3 Endpoint s
8.3.1 Primary Endpoint(s)
Change from baseline in HbA1c at Week 24.
8.3.2 Secondary Endpoint(s)
The change from baseline in FPG at Week 24
The percentage of subjects who require glycemic rescue medication or discontinuation due to 
lack of gl ycemic control over 24 weeks double -blind treatment.
The percentage of subjects with baseline HbA1c > 7% who achieve HbA1c level <7% at 
Week24.
8.3.3 Exploratory Endpoint(s) 
The PK and exposure -response relationship of dapagliflozin based on the collection of 
population PK samples
The mean change from baseline in HbA1c achieve d with dapagliflozin at Week 
52
The mean change from baseline in FPG achieved with dapagliflozin at Week 52
The percentage of subjects who require glycemic rescue medication or discontinuation due to 
lack of gl ycemic control during 52 weeks treatment period.
The percentage of subjects with baseline HbA1c > 7% who achieve a HbA1c level < 7% at 
Week 52
8.4 Analyses
8.4.1 Demographics and Baseline Characteristics
Demographic and baseline characteristics will be summarized using frequency  distributions and 
descriptive statistics using the Randomized Subjects Data Set, for each treatment group as well as 
for all subjects combined. No statistical tests will be perform ed to compare treatment groups at 
baseline.
8.4.2 Efficacy Analyses
8.4.2.1 Primary Analysis
The primary  analysis of the primary  endpoint, change in HbA1c from baseline to Week 24, will 
be based on a mixed model with repeated measures (MMRM) including all scheduled time points 
following randomization up to and including Week 24. This model will include patients in the 
Randomized Subjects Data Set who have a baseline measurement and at least one post-baseline 
measurement. The primary anal ysis will only  include measurement s prior to the administration of 
rescue medication. Measurements made following rescue administration will be included in 
sensitivity  analysis. Various sensitivity  analyses will be specified in the Statistical Analy sis Plan 
to assess the robustness of the primary  analyses, including sensitivity  analyses of all data pre -and 
post-rescue.
The SAS procedure PROC MIXED will be used for primary  analyses. The primary  analysis model 
will include the fixed categorical effects of treatment, week, randomization strati fication factor (as 
warranted), and treatment- by-week interaction as well as the continuous fixed covariates of 
Clinical Protocol MB102138
BMS -512148 dapagliflozin
Revised Protocol No: 03
Date: 20-Sep- 2017 62baseline measurement and baseline measurement -by-week interaction. An unstructured matrix for 
the within -patient error variance -covariance will be used. The denominator degrees of freedom 
will be calculated according to the Kenward -Roger method. A number of back -up models will be 
defined in the Statistical Analysis Plan in case of non -convergence of the preferred model or other 
issues. 
Point estimates and 95% confidence intervals for the mean change in HbA1c for each treatment 
group as well as the difference in the estimated mean change between the dapagliflozin treatment 
group and placebo will be calculated. The p- value of the difference in Week 24 estimates between 
dapagliflozin and placebo will be presented.
8.4.2.2 Secondary Analyses
The family -wise Ty pe I error rate related to the primary  and secondary  efficacy  endpoints will be 
controlled at the 2 -sided 0.05 level by  using a hierarchical closed testi ng procedure. 
Specificall y, if the primary  comparison in change in HbA1c between the dapagliflozin 10mg 
treatment group and the placebo group is significant at the 0.05 level, then the statistical testing 
for the secondary efficacy endpoints will be perf ormed. In order to control the family -wise T ypeI 
error rate across the primary  and secondary  endpoints, the interpretation of the statistical 
significance of treatment comparison for each secondary  efficacy  endpoint will be done using a 
hierarchical close d testing procedure which will be defined in the Statistical Analy sis Plan, prior 
to unblinding of the treatment assignments.
Similar methods to the primary  analysis will be used in analyses of continuous secondary 
endpoints. The methodology of Zhang, Tsiatis and Davidian22and Tsiatis, Davidian, Zhang,and 
Lu23with adjustment for baseline measurement and randomization strata will be used in analy ses 
of categorical secondary  endpoints, and details will be provided in the Statistical Analy sis Plan.
8.4.2.3 Exploratory Analyses
Similar methods to the primary  and secondary  analyses will be used for analy ses of exploratory  
endpoints. Between group differences in the mean change from baseline for continuous 
exploratory  variables (HbA1c and FPG) will not be genera ted for thelong-term (LT)period in 
short -term (ST) +LT analy ses, and statistical comparisons will not be performed. Similarl y, 
between group differences in proportions of dichotomous exploratory variables will not be 
generated for the LT period in ST+LT analyses, and statistical comparisons will also not be 
performed.
Analy sis of the PK endpoint is described in Section 8.4.4.
8.4.3 Safety Analyses
Safety  analy ses will include treatment group summaries of the incidence of AEs and marked 
laboratory  abnormalities, the percentages of subjects experiencing hypogly cemia as well as the 
number and severit y of hy pogly cemic events, the incidence of elevated plasma ketone level ,vital 
signs, and laboratory  test parameters. 
Clinical Protocol MB102138
BMS -512148 dapagliflozin
Revised Protocol No: 03
Date: 20-Sep- 2017 63The assessment of safety will be based on the analyses of AEs, vital signs, physical examinations, 
ECGs, hypoglycemia , elevated plasma ketone level, and clinical laboratory  evaluat ions. All safet y 
analyses will be performed using the Treated Subjects Data Set. 
The number and percent of patients with at least one AE will be summarized by treatment group, 
including summaries of AEs, SAEs, AEs leading to discontinuation of study medication, and AEs
of special interest. Summaries will include the number of patients with events by specified system 
organ classes and preferred terms. 
Summar y statistics will be presented at each assessment visit for the continuous safety  parameters. 
Descriptive statistics of changes from baseline by study  visits will also be presented. A frequency 
table of results of categorical safety  parameters will be produced. Furthermore, laboratory /ECG 
abnormalities will be analy zed by shift tables. The number and percent of subjects with values 
meeting marked/notable abnormality  criteria will be summarized for each treatment group for vital 
signs, lab, and ECG parameter s.
8.4.4 Pharmacokinetic A nalyses
Dapagliflozin plasma concentration will be listed and summarized by sample collection day and 
time. The anal yses will be performed using the Pharmacokinetic Anal ysis Data Set.
8.4.5 Biomarker Analyses
Not applicable
8.4.6 Outcomes Research Analyses
Not applicable
8.4.7 Other Analyses 
Not applicable
8.5 Interim A nalyses
Not applicable
9 STUDY MA NAGEMENT
9.1 Compliance
9.1.1 Compliance with the Protocol and Protocol Revisions
The study  shall be conducted as described in this approved protocol. All revisions to the protocol 
must be discussed with, and be prepared b y, the Sponsor or designee. The Investigator should not 
implement any deviation or change to the protocol without prior review and documented 
approval/favorable opinion from the IRB/IEC of an amendment, except where necessary  to 
eliminate an immediate hazard(s) to study  subjects. 
If a deviation or change to a protocol is implemented to eliminate an immediate hazard(s) prio r to 
obtaining IRB/IEC approval/favorable opinion, as soon as possible the deviation or change will be 
submitted to:
IRB/IEC for review and approval/favorable opinion
Clinical Protocol MB102138
BMS -512148 dapagliflozin
Revised Protocol No: 03
Date: 20-Sep- 2017 64the Sponsor/Designee
Regulatory  Authority (ies), if required by  local regulations
Document ation of approval signed by the chairperson or designee of the IRB(s)/IEC(s) must be 
sent to the Sponsor or designee.
If an amendment substantially  alters the study  design or increases the potential risk to the subject: 
(1) the consent form must be revised and submitted to the IRB(s)/IEC(s) for review and 
approval/favorable opinion; (2) the revised form must be used to obtain consent from subjects 
currentl y enrolled in the study  if they  are affected by  the amendment; and (3) the new form must 
be used to obt ain consent from new subjects prior to enrollment.
If the revision is done via an administrative letter, investigators must inform their I RB(s)/IEC(s).
9.1.2 Monitoring
The Sponsor or designee representatives will review data centrally  to identify  potential issues to 
determine a schedule of on -site visits for targeted review of stud y records.
Representatives of the Sponsor or designee must be allowed to visit all study  site locations 
periodicall y to assess the data qualit y and study  integrit y. On site they will review study  records 
and directl y compare them with source documents, discuss the conduct of the study  with the
Investigator, and verify  that the facilities remain acceptable.
In addition, the study  may be evaluated by the Sponsor or designee internal auditors and 
government inspectors who must be allowed access to CRFs, source documents, other stud y files, 
and study  facilities. TheSponsor or designee audit reports will be kept confidential.
The Investigator must notify  the Sponsor or designee promptl y of any inspections scheduled by 
regulatory  authorities, and promptly  forward copies of inspection reports to the Sponsor or 
designee . 
9.1.2.1 Source Documentation
The Investigator is responsible for ensuring that the source data are accurate, legible, 
contemporaneous, original and attributable, whether the data are hand -written on paper or entered 
electronically . If source data are created (first entered), modified, maintained, archived, retrieved, 
or transmitted electronically via computerized systems (and/or anyother kind of electronic 
devices) as part of regulated clinical trial activities, such systems must be compliant with all 
applicable laws and regulations governing use of electronic records and/or electronic signatures. 
Such systems may include, but are not limited to, electronic medical/health records (EMRs/EHRs), 
AEtracking/reporting, protocol required assessments, and/or drug accountability  records).
When paper records from such systems are used in place of electronic format to perform regulated 
activi ties, such paper records should be certified copies. A certified copy consists of a copy  of 
original information that has been verified, as indicated by a
 dated signature, as an exact copy 
having all of the same attributes and information as the original. 
Clinical Protocol MB102138
BMS -512148 dapagliflozin
Revised Protocol No: 03
Date: 20-Sep- 2017 659.1.3 Investigational Site Training
AstraZeneca or designee will provide quality  investigational staff training prior to study  initiation. 
Training topics will include but are not limited to: GCP, AE reporting, study details and procedure, 
electronic CRFs, stud ydocumentation, informed consent, and enrollment of WOCBP.
9.2 Records
9.2.1 Records Retention
The Investigator must retain all study  records and source documents for the maximum period 
required by applicable regulations and guidelines, or institution procedures, or for the period 
specified by the Sponsor or designee, whichever is longer. The Investigator must contact the 
Sponsor or designee prior to destro ying any  records associated with the study .
The Sponsor or designee will notify  the Investigator when the study records are no longer needed.
If the Investigator withdraws from the study  (e.g., relocation, retirement), the records shall be 
transferred to a mutuall y agreed upon designee (e.g., another investigator, IRB). Notice of such 
transfer will be given in writing to the Sponsor or designee .
9.2.2 Study Drug Records 
It is the responsibility  of the Investigator to ensure that a current disposition record of study  drug 
(inventoried and dispense d) is maintained at the study  site to include IP and the following 
non-IP(s). Records or logs must comply  with applicable regulations and guidelines and should 
include:
amount received and placed in storage area
amount currentl y in storage area
label ident ification number or batch number
amount dispensed to and returned b y each subject, including unique subject identifiers
amount transferred to another area /site for dispensing or storage
nonstudy  disposition ( e.g., lost, wasted )
amount destroy ed at study  site, if applicable
amount returned to the Sponsor or designee
retain samples for bioavailability /bioequivalence, if applicable
dates and initials of person responsible for IPdispensing/accountability , as per the Delegation 
of Authority  Form
The Sponsor or designee will provide forms to facilitate inventory  control if the investigational 
site does not have an established sy stem that meets these requirements .
Clinical Protocol MB102138
BMS -512148 dapagliflozin
Revised Protocol No: 03
Date: 20-Sep- 2017 669.2.3 Case Report Forms
An investigator is required to prepare and maintain adequate and accurate case hist ories designed 
to record all observations and other data pertinent to the investigation on each individual treated 
or entered as a control in the investigation. Data that are derived from source documents and 
reported on the CRF must be consistent with thesource documents or the discrepancies must be 
explained. Additional clinical information may be collected and analyzed in an effort to enhance 
understanding of product safet y. CRFs may  be requested for AEs and/or laboratory  abnormalities 
that are reported or identified during the course of the study .
For sites using the Sponsor’s electronic data capture tool, electronic CRFs will be prepared for all 
data collection fields except for fields specific to SAEs and pregnancy , which will be reported on 
the elect ronic SAE form and Pregnancy  Surveillance form, respectivel y. If an electronic SAE form 
is not available, a paper SAE form can be used.
The confidentialit y of records that could identify  subjects must be protected, respecting the privacy 
and confidentialit y rules in accordance with the applicable regulatory requirement(s).
The Investigator will maintain a signature sheet to document signatures and initials of all persons 
authorized to make entries and/or corrections on CRFs. 
The completed CRF, including any paper or electronic SAE/pregnancy  CRFs, must be promptl y 
reviewed, signed, and dated by the Investigator or qualified physician who is a subinvestigator and 
who is delegated this task on the Delegation of Authority  Form. For electronic CRFs, review and 
approval/signature is completed electronically  through the Sponsor’s electronic data capture tool. 
The Investigator must retain a cop y of the CRFs including records of the changes and corrections.
Each individual electronically  signing electronic CRFs must meet the Sponsor’s training 
requirements and must only access the Sponsor or designee’s electronic data capture tool using the 
unique user account provided by  the Sponsor. User accounts are not to be shared or reassigned to 
other individuals.
9.3 Clinical Stud y Report and Publications
A Signatory  Investigator must be selected to 
sign the CSR.
For this protocol, the Signatory Investigator will be selected as appropriate based on the following 
criteria:
External Principal I nvestigator designated at protocol devel opment
National Coordinating Investigator 
Study  Steering Committee chair or their designee
Subject recruitment ( e.g., among the top quartile of enrollers)
Involvement in trial design
Regional representation (e.g., among top quartile of enrollers from a specified region or 
country )
Other criteria (as determined by  the study  team)
Clinical Protocol MB102138
BMS -512148 dapagliflozin
Revised Protocol No: 03
Date: 20-Sep- 2017 67The data collected during this study  are confidential and proprietary  to the Sponsor or designee. 
Any publications or abstracts arising from this study  must adhere to the publication requirements 
set forth in the clinical trial agreement (CTA) governing [Study  site or Investigator] participation 
in the study . These requirements include, but are not limited to, submitting proposed publications 
to the Sponsor or designee at t he earliest practicable time prior to submission or presentation and 
otherwise within the time period set forth in the CTA.
Clinical Protocol MB102138
BMS -512148 dapagliflozin
Revised Protocol No: 03
Date: 20-Sep- 2017 6810 GLOSSA RY OF TERMS
Term Definition
Com plete AbstinenceIf one form of contraception is required, Complete Abstinence is defined 
as complete avoidance of heterosexual intercourse and is an acceptable 
form of contraception for all study drugs. Female subjects must continue 
to have pregnancy tests. Acceptable alternate methods of highly effective 
contraception must be discussed in the eve nt that the subject chooses to 
forego complete abstinence.
If tw o forms of contraception is required, Complete abstinence is defined 
as complete avoidance of heterosexual intercourse and is an acceptable 
form of contraception for all study drugs. Subjects who choose complete 
abstinence are not required to use a second method of contraception, but 
female subjects must continue to have pregnancy tests. Acceptable 
alternate methods of highly effective contraception must be discussed in 
the event that the subje ct chooses to forego complete abstinence.
Expanded definition Com plete abstinence as defined as complete 
avoidance of heterosexual intercourse is an acceptable form of 
contraception for all study drugs. This also means that abstinence is the 
preferred and usual lifestyle of the patient. This does not mean periodic 
abstinence ( e.g., calendar, ovulation, symptothermal, profession of 
abstinence for entry into a clinical trial, post -ovulation methods) and 
withdrawal, which are not acceptable methods of contraception. Subjects 
who choose complete abstinence are not required to use a second method 
of contraception, but female subjects must continue to have pregnancy 
tests. Acceptable alternate methods of highly effective contraception must 
be discussed in the event that the subject chooses to forego complete 
abstinence .
Clinical Protocol MB102138
BMS -512148 dapagliflozin
Revised Protocol No: 03
Date: 20-Sep- 2017 6911 LIST OF ABBREVIA TIONS
Term Definition
ADA American Diabetes Association
AE adverse event
ALT alanine aminotransferase
AST aspartate aminotransferase
AT aminotransferases
AZ AstraZeneca
BMI body  mass index
BMS Bristol -Myers Squibb
BP blood pressure
CFR Code of Federal Regulations 
CRF case report form
CSR Clinical Study  Report
CTA Clinical Trial Agreement
DILI drug-induced liver injury
DKA diabetic ketoacidosis
dL deciliter
DMC Data Monitoring Committee
ECG electrocardiogram
eCRF electronic case report form
eGFR estimated glomerular filtration rate
EU European Union
ETD early treatment discontinuation
FDA Food and Drug Administration
FPG fasting plasma glucose
g gram
GAD glutamic acid decarbox ylase
GCP Good Clinical Practice
GMP Good Manufacturing Practice
HAV hepatitis A virus
Clinical Protocol MB102138
BMS -512148 dapagliflozin
Revised Protocol No: 03
Date: 20-Sep- 2017 70Term Definition
HbA1c glycosylated hemoglobin
HBsAg hepatitis B surface antigen
HCV hepatitis C virus
HR heart rate
IA-2 protein ty rosine phosphatase -like protein antibodies
IB investigator brochure
ICF informed consent form
ICH International Conference on Harmonisation 
IEC Independent Ethics Committee
IMP investigational medicinal product
IP investigational (medicinal) product
IR immediate release
IRB Institutional Review Board
IU international unit
IUD intrauterine device
IWRS Interactive Web / Voice Recognition Sy stem
kg kilogram
L liter
LT long-term
MDRD Modified Diet in Renal Disease, stud y equation
mg milligram
min minute
mL milliliter
MMRM Mixed effect Model Repeat Measurement
MODY maturity  onset diabetes of the y oung
non-IMP non-investigational medicinal product 
non-IP non-investigational (medicinal) product
OAD oral antidiabetic
PD pharmacod ynamics
PK pharmacokinetics
Clinical Protocol MB102138
BMS -512148 dapagliflozin
Revised Protocol No: 03
Date: 20-Sep- 2017 71Term Definition
PPG postprandial glucose
SAE serious adverse event
SGL T-2 sodium glucose cotransporter-2
SMBG self-monitored blood glucose
ST short -term
TB total bilirubin
T2DM type 2 diabetes mellitus
TSH thyroid stimulating hormone
UK United Kingdom
ULN upper limit of normal
UKPDS UK Prospective Diabetes Study
UTI urinary  tract infection 
US United States (of America)
WHO World Health Organization
WOCBP women of childbearing potential
XR extended release
Clinical Protocol MB102138
BMS -512148 dapagliflozin
Revised Protocol No: 03
Date: 20-Sep- 2017 7212 REFERENCES
1.Alberti G, Zimmet P, Shaw J, Bloomgarden Z, Kaufman F, Silink M, et al. Type 2diabetes 
in the y oung: the evolving epidemic. Diabetes Care 2004;27:1798 -811
2.International Diabetes Federation Clinical Guidelines Task Force. Global guideline for 
type 2 diabetes. Brussels: International Diabetes Federation; 2005. Available from: 
http://www.idf.org/webdata/docs/IDF%20GGT2D.pdf. Accessed on 13 February 2008.
3.American Diabetes Association. Type 2 diabetes in children and adolescents. Diabetes 
Care 2000;23:381 -9.
4.American Diabetes Association. Standards of medical care in diabetes 2008. Diab etes Care 
2008;31(Suppl 1):S12-54.
5.Goran MI, Ball GDC, Cruz ML. Obesity  and risk of type 2 diabetes and cardiovascular 
disease in children and adolescents. J Clin Endocrinol Metab 2003;88:1417-27.
6.Krakoff J, Hanson RL, Kobes S, Knowler WC. Comparison of the effect of plasma glucose 
concentrations on microvascular disease between Pima I ndian y ouths and adults. Diabetes 
Care 2001;24:1023 -8.
7.Dean HJ, Sellers EAC. Comorbidities and microvascular complications of ty pe 2 diabetes 
in children and adolescents. Pediatr Diabetes 2007; 8 (Suppl 9):35-41.
8.Eppens MC, Craig ME, Cusumano J, Hing S, Chang AKF, Howard NJ, et al. Prevalence 
of diabetes complications in adolescents with type 2 compared with type 1 diabetes. 
Diabetes Care 2006;29:1300 -
6.
9.Bloomgarden, ZT. Type 2diabetes in the young. The evolving epidemic. Diabetes Care 
2004;27:998 -1010.
10.Diabetes Control and Complications Trial Research Group. The Effect of Intensive 
Treatment of Diabetes on the Development and Progression of Long -Term Complications 
in Insulin -Dependent Diabetes Mellitus. N Engl J Med 1993;329:977- 86.
11.Pinhas- Hamiel O, Dolan LM, Daniels SR, Standiford D, Khoury  PR, Zeitler P. Increased 
incidence of non-insulin -dependent diabetes mellitus among adolescents. J Pediatr 
1996;128(5 Pt 1):608 -15.
12.Bingley  P, Bonifacio E, Ziegler A, Schatz D, Atkinson M, Eisenbarth G and the 
Immunology  of Diabetes Society . Proposed Guidelines on Screening for Risk of Type 1 
Diabetes. Diabetes Care 2001;24(2):398.
13.Ehtisham S, Hattersley  AT, Dunger DB, Barrett TG. Firs t UK survey  of paediatric ty pe 2 
diabetes and MODY. Arch Dis Child 2004;89:526-9.
14.Neu A, Feldhahn L, Ehehalt S, Hub R, Ranke M. Ty pe 2 diabetes mellitus in children and 
adolescents is still a rare disease in German y: A population- based assessment of the 
prevalence of type 2 diabetes and MODY in patients aged 0-20 years. Peds Diabetes 
2009;10(7):468 -73.
Clinical Protocol MB102138
BMS -512148 dapagliflozin
Revised Protocol No: 03
Date: 20-Sep- 2017 7315.Zachrisson I, Tibell C, Bang P, Ortquist E. Prevalence of type 2 diabetes among known 
cases of diabetes aged 0 -18 years in Sweden. J Pediatr Endocrinol Metab 2003;16:919 -55.
16.Kestelman P. et. al., Efficacy of the Simultaneous Use of Condoms and Spermicides 
Family  Planning Perspectives.Vol 23 (5); October 1991.
17.Gabbay  MB, Thomas J, Gibbs A, Hold P. A Randomized Crossover Trial of The Impact 
of Additional Spermic ide on Condom Failure Rates. Sex Transm Dis 2008; 35: 862 -8.
18.Schwartz GJ, Munoz A, Schneider MF, Mak RH, Kaskel F, Warad y BA, Furth SL. New 
Equations to Estimate GFR in Children with CKD. JASN 2009; 20: 629 -637.
19.Levey  AS, Coresh J, Greene T, Marsh J, Steve ns LA, Kusek JW, Van Lente F; Chronic 
Kidney  Disease Epidemiology  Collaboration. Expressing the Modification of Diet in Renal 
Disease Study  Equation for Estimating Glomerular Filtration Rate with Standardized 
Serum Creatinine Values. Clin Chem. 2007 Apr;53 (4):766-72.
20.Global IDF/ISPAD Guideline for Diabetes in Childhood and Adolescence, available at 
https://www.idf.org/sites/default/files/Diabetes -in-Childhood- and-Adolescence -
Guidelines.pdf
21.http://care.diabetesjournals.org/content/earl y/2013/04/12/dc12-2480.full.pdf
22.Zhang M., A.A. Tsiatis, and M. Davidian, Improving efficiency  of inferences in 
randomized clinical trials using auxiliary  covariates. Biometrics, 2008. 64(3): 707 -715.
23.Tsiatis, A.A., et al., Covariate adjustment for two-sample treatment comparison s in 
randomized clinical trials: a principled yet flexible approach. Stat Med, 2008. 27(23): 
4658-4677.
Clinical Protocol MB102138
BMS -512148 dapagliflozin
Revised Protocol No: 03
Date: 20-Sep- 2017 74APPENDIX 1 CENTRA L LA BORA TORY ASSESSMENTS
Blood and urine samples will be obtained at specified time points for laboratory  evaluations. The 
central laboratory for this study  will perform the analysis of all scheduled laboratory tests and will 
provide reference ranges for these tests. The detailed methods for specimen collection, handling, 
processing, shipping, and storage will be supplied in the Investigator’s Laboratory  Manual 
provided by  the Central Laboratory . All clinical laboratory  tests will be performed by  the Central 
Laboratory  or designated reference laboratory .
For the duration of the double -blind treatment period (Day  1 to Week 24), the HbA1c and the 
urinary  glucose values, including the urinary  glucose:creatinine ratio, will be masked to the 
Sponsor and will not be available to the Investigator. 
During the open -label long-term extension period (after the Week 24 visit to Week 52), the above 
measuremen
ts will be unmasked and available to the Sponsor and the Investigator.
The following sections indicate the laboratory  tests required for this study . For countries using 
conventional units, the results will be reported using conventional units. For countrie s using 
SIunits, the results will be reported using SI  units. In cases of differences in the units as listed in 
this protocol compared to the units on the central laboratory  reports, the units from the central 
laboratory  reports will be used. 
PROTOCOL -SPECIFIC CENTRAL LABORATORY ASSESSMENTS:
HbA1c (%, mmol/mol)
Fasting plasma glucose ( FPG)(mg/dL, mmol/L )
Fasting serum lipid profile: 
Total -C (mg/dL, mmol/L)
Calculated LDL- C (mg/dL, mmol/L)
Except screening period, reflex testing will occur for Direct LDL-C if TG> 400 mg/dL 
(4.52 mmol/L)
HDL -C (mg/dL, mmol/L)
TG (mg/dL, mmol/L)
Enrollment -Specific Reflex Testing
Thyroid stimulating hormone (TSH)
Reflex Testing: abnormal TSH value at enrollment will be further evaluated by free T4.
Hepatitis Screen Panel:
Anti- hepatitis C virus antibody
Hepatitis B surface antigen
Anti- hepatitis A virus IgM
Reflex Testing: Low positive and positive results require confirmatory testing.
Clinical Protocol MB102138
BMS -512148 dapagliflozin
Revised Protocol No: 03
Date: 20-Sep- 2017 75Specialized Liver Panel:
For subjects who are being monitored frequently  as a result ofconfirmed aspartate 
aminotransferase (AST) and/or alanine aminotransferase (ALT) > 3X upper limit of normal 
(ULN), additional central laboratory  tests will be performed within 3days of receipt of 
confirmatory  results. These laboratory  tests will study  the possible causes of the increased ALT 
and/or AST and/or TB, and may  include, but are not limited to, the following tests:
Hepatitis A IgM
Hepatitis BsAg
Hepatitis B Core Ab IgM
Hepatitis C virus RNA or RIBA
Hepatitis C Ab
Hepatitis E IgM
Epstein- Barr virus (EBV) IgM Ab
Lactate dehy drogenase (LDH)
Gamma -glutam yl-transpeptidase (GGT)
Carbohy drate deficient transferrin (CDT)
Prothrombin time (PT/INR)
Iron panel - iron, ferritin, total iron binding capacity  (TIBC)
Immunology  panel including antinuclear antibody  (ANA), anti-smooth muscle antibody 
(SMA) and anti -liver/kidney  microsomal antibody (Anti -LKM)
Anti- tissue transglutaminase antibod y
Liver Discontinuation Panel:
For subjects who are discontinued from the study  as a result of sustained elevated liver safet y 
abnormalities, additional central laboratory  tests will be performed at the time of Early 
Termination (End -of-Treatment) visit. Similar to the Specialized Liver Panel, these laboratory  tests 
will study  the possible causes of the increased ALT and/or AST and/or TB, and may  include, but 
are not limited to, the following tests:
Cytomegalovirus (CMV) IgM Ab
Herpes simplex virus (HSV) 1 and 2
Ceruloplasmin
Toxoplasmosis
Alpha- 1 antitry psin
For specific details regarding the Specialized Liver Panel and the Liver Discontinuation Panel 
laboratory  tests, refer to the Central Laboratory  Manual for this study .
Clinical Protocol MB102138
BMS -512148 dapagliflozin
Revised Protocol No: 03
Date: 20-Sep- 2017 76Standard Safety Laboratory Panels:
Table Appendix 1: Standard Safety Laboratory Panels
Hem atology
Hem oglobin (g/dL, g/L)
Hem atocrit (%, V/V)
Red blood cell (RBC) (x106/UL, x1012/L)
RBC count indices: 
Mean Cell Volume (MCV) (fL) 
Mean Cell Hemoglobin (MCH) (pg/cell)
Mean Cell Hemoglobin Concentration (MCHC) (gHb/dL, gHb/L)
White blood cell Count and Differential
Platelet count (x109/L)
Serum Chemistry
AST (IU/L)
ALT (IU/L)
ALK -P (IU/L) 
Total Bilirubin (mg/dL, mol/L)
Serum Creatinine (Scr) used to calculate estimated glomerular filtration rate (eGFR) according to the 
following:
In subjects < 18 years of age: Schwarz formula1eGFR (mL/min/1.73 m2) = 0.413 *(height (cms)/serum 
creatinine (mg /dL)
In subjects 18 years of age: MDRD Equation2GFR (mL/min/1.73 m2) =175× (Serum creatinine) -
1.154 × (Age) -0.203 × (0.742 if female) × (1.212 if African American)
Results will be reported to the sites and the Sponsor.
Sodium (mEq/L, mmol/L)
Potassium (mEq/L, mmol/L)
Chloride (mEq/L, mmol/L)
Calcium (mg/dL, mmol/L)
Magnesium (mEq/L, mmol/L)
Phosphorus (mg/dL, mmol/L)
Total Protein (g/dL, g/L)
Uric acid (mg/dL, mol/L)
Urine Analyses
Creatinine
Calculated Urinary albumin:creatinine ratio (UACR)
Urine HCG pregnancy test for WOCBP (HCG minimum sensitivity of 25 IU/L; performed at site or at home). 
If a urine HCG test is positive, a blood specimen will be obtained and a serum pregnancy test will be performed 
by the ce ntral laboratory for confirmation.
Clinical Protocol MB102138
BMS -512148 dapagliflozin
Revised Protocol No: 03
Date: 20-Sep- 2017 77Table Appendix 1: Standard Safety Laboratory Panels
Spot urine:
Urinary glucose:creatinine ratio
Urinalysis with microscopy :
Hem aturia
Clinical Protocol MB102138
BMS -512148 dapagliflozin
Revised Protocol No: 03
Date: 20-Sep- 2017 78APPENDIX 2 SUSTA INED ELEVA TED LIVER SA FETY ABNORM ALITIES FLOW CHA RT
Obtain confirmatory repeat AST, ALT, ALK -P and TB within 
3 days. Do NOT hold study medicationStep 1: Central Laboratory Alert Criteria
ALT and/or AST   3X ULN
. 
.Step 2a : 
If repeat ALT AND
AST  3X ULNStep 2b : 
If repeat ALT and/or AST 
3X ULN BUT 5X ULN 
AND TB 2.0X ULNaStep 2c : 
If repeat ALT and/or AST 
5X ULN BUT 10X 
ULN and TB 2.0X ULNStep 2d : 
If repeat ALT and/or AST 
3X ULN with a second 
confirmed TB 2.0X ULNaStep 2e : 
If repeat ALT and/or 
AST 10X ULN
-Continue the subject 
in the treatment period 
according to the 
original visit schedule, 
unless otherwise 
contraindicated.-Discontinue the subject immediately.
-Notify the Sponsor.
-Perform the end -of-treatment visit and additional assessments, 
including the liver discontinuation panel.b
-Obtain confirmatory repeat AST, ALT, ALK -P and TB 
every 3 days .c-Continue study medication.
-Perform additional 
assessments, including the 
specialized liver panel.b
-Obtain confirmatory 
repeat AST, ALT, ALK-P 
and TB every 3 days.c
Each time AST, ALT, ALK -P and TB results are received, go 
back to Step 2 to review and implement the appropriate follow- up-Continue study medication.
-Perform additional 
assessments, i ncluding the 
specialized liver panel.b
-Obtain confirmatory 
repeat AST, ALT, ALK-P 
and TB every 3 days .c
If repeat ALT and/or AST 5X ULN for 14 consecutive days, at 
any time after initial confirmatory results
aIn subjects with repeat ALT or AST 3X ULN but 10X ULN, only subjects with TB 2.0X ULN at Step 1 should be followed according to Step 2b. Subjects with an 
initial TB and confirmatory repeat TB 2.0X ULN should be followed according to Step 2d.
bRefer to section 5.3.4 for details on additional assessments to be performed (AE assessment, PE, review of current medical history including focused review of risk factors 
for liver diseases and collection of blood samples [specialized liver panel or liver dis continuation panel]).
cConfirmatory repeat AST, ALT, ALK -P and TB should be obtained every 3 days following receipt of prior laboratory results, until the ALT and AST are 2X ULN or until 
ALT and AST are at or below baseline levels. The frequency of ret esting can decrease to once a week or less if abnormalities stabilize and the subject is asymptomatic.
Clinical Protocol MB102138
BMS -512148 dapagliflozin
Revised Protocol No: 03
Date: 20-Sep- 2017 79APPENDIX 3 TANNER ASSESSMENT SCA LE
The Tanner Scale (also known as Tanner Staging) is a measure of pubertal development (sexual 
maturation) in children and adolescents with components described for each sex, rated separately 
on a scale of stage one to stage five. The stages define physical measurement of development based 
on external primary  and secondary  sexual characteristics. Females are classified with regard to 
breast and pubic hair characteristics. Males are classified with regard to genitalia and pubic hair 
characteristics. 
A qualita tive determination of the subject ’s sexual maturity  rating on a scale of 1 to 5 will be 
determined according to those criteria established by Tanner3,4(summarized in Tables 1 and 
2below). Based on the level of comfort by the Investigator, caregiver, or study  subject, the 
measure of sexual maturity  may be obtained by 1) visually  observing the level of development 
after the subject disrobes or 2) requesting the caregiver or subject point to the level of maturit y 
from a description or selection of pictures that exhibit the various stages of matur ity.
Table 1: Classification of Sex Maturity Stages in Girls
Stage Pubic Hair Breasts
1 Preadolescent Preadolescent
2Sparse grow th of long, slightly pigmented dow ny 
hair, straight or only slightly curled; appears 
chiefly along the labiaBreast bud stage; elevation of breast and 
papilla as a small mound; enlargement of 
areola diameter
3 Darker, beginning to curl, increased amountFurther enlargement of breast and areola w ith 
no separation of their contours
4Resembles adult type but the area covered is still 
considerably smaller than in most adults; no 
spread to the medial surface of the thighsProjection of areola and papilla form a 
secondary mound above the level of the 
breast
5Adult in quantity and type, spread to medial 
surface of thighsMature; projection of papilla only due to 
recession of the areola to the general contour 
of the breast
Clinical Protocol MB102138
BMS -512148 dapagliflozin
Revised Protocol No: 03
Date: 20-Sep- 2017 80Table 2: Classification of Sex Maturity Stages in Boys
Stage Pubic Hair Genitalia
1 None Preadolescent
2Sparse grow th of long, slightly pigmented dow ny 
hair, straight or only slightly curled; appears 
chiefly at the base of the penisScrotum and testes have enlarged; change in 
texture of the scrotal skin with some 
reddening
3Darker, coarser, and more curled; spreads sparsely 
over the junction of the pubesGrow th of the penis, mainly in length but 
with some increase in breadth; further growth 
of testes and scrotum
4Resembles adult type but the area covered is still 
considerably smaller than in most adults; no 
spread to the medial surface of the thighsPenis further enlarged in length and breadth 
with development of glans. Testes and 
scrotum further enlarged with further 
darkening of the scrotal skin
5Adult in quantity and type, spread to medial 
surface of thighsAdult size and shape. No further enlargement 
of testes and scrotum
Additional materials to aid in the Tanner Stage assessment will be provided upon request.
"-"5=2'----
